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CDC Adoption of ACIP Recommendations for MMWR 
Recommendations and Reports, MMWR Policy Notes, and 
Immunization Schedules (Child/Adolescent, Adult)
ACIP is chartered as a federal advisory committee to provide 
expert external advice and guidance to the Director of the 
Centers for Disease Control and Prevention (CDC) on use 
of vaccines and related agents for the control of vaccine-
preventable diseases in the civilian population of the United 
States. Recommendations for routine use of vaccines in 
children and adolescents are harmonized to the greatest 
extent possible with recommendations made by the American 
Academy of Pediatrics (AAP), the American Academy of 
Family Physicians (AAFP), and the American College of 
Obstetricians and Gynecologists (ACOG). Recommendations 
for routine use of vaccines in adults are harmonized with 
recommendations of AAFP, ACOG, and the American College 
of Physicians (ACP). ACIP recommendations adopted by the 
CDC Director become agency guidelines on the date published 
in the Morbidity and Mortality Weekly Report (MMWR).
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Summary
This report is a compendium of all current recommendations for the prevention of measles, rubella, congenital rubella syndrome 
(CRS), and mumps. The report presents the recent revisions adopted by the Advisory Committee on Immunization Practices 
(ACIP) on October 24, 2012, and also summarizes all existing ACIP recommendations that have been published previously 
during 1998–2011 (CDC. Measles, mumps, and rubella—vaccine use and strategies for elimination of measles, rubella, and 
congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices 
[ACIP]. MMWR 1998;47[No. RR-8]; CDC. Revised ACIP recommendation for avoiding pregnancy after receiving a rubella-
containing vaccine. MMWR 2001;50:1117; CDC. Updated recommendations of the Advisory Committee on Immunization 
Practices [ACIP] for the control and elimination of mumps. MMWR 2006;55:629–30; and, CDC. Immunization of health-
care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011;60[No. RR-7]).
Currently, ACIP recommends 2 doses of MMR vaccine routinely for children with the first dose administered at age 12 through 
15 months and the second dose administered at age 4 through 6 years before school entry. Two doses are recommended for adults at 
high risk for exposure and transmission (e.g., students attending colleges or other post-high school educational institutions, health-
care personnel, and international travelers) and 1 dose for other adults aged ≥18 years. For prevention of rubella, 1 dose of MMR 
vaccine is recommended for persons aged ≥12 months.
At the October 24, 2012 meeting, ACIP adopted the following revisions, which are published here for the first time. These included:
•	 For acceptable evidence of immunity, removing documentation of physician diagnosed disease as an acceptable criterion 
for evidence of immunity for measles and mumps, and including laboratory confirmation of disease as a criterion for 
acceptable evidence of immunity for measles, rubella, and mumps.
•	 For persons with human immunodeficiency virus (HIV) infection, expanding recommendations for vaccination to all 
persons aged ≥12 months with HIV infection who do not have evidence of current severe immunosuppression; recommending 
revaccination of persons with perinatal HIV infection who were vaccinated before establishment of effective antiretroviral 
therapy (ART) with 2 appropriately spaced doses of MMR vaccine once effective ART has been established; and changing 
the recommended timing of the 2 doses of MMR vaccine for HIV-infected persons to age 12 through 15 months and 
4 through 6 years.
•	 For measles postexposure prophylaxis, expanding recommendations for use of immune globulin administered intramuscularly 
(IGIM) to include infants aged birth to 6 months exposed to measles; increasing the recommended dose of IGIM for 
immunocompetent persons; and recommending use of immune globulin administered intravenously (IGIV) for severely 
immunocompromised persons and pregnant women without evidence of measles immunity who are exposed to measles.
As a compendium of all current recommendations for the prevention of measles, rubella, congenital rubella syndrome (CRS), 
and mumps, the information in this report is intended for use by clinicians as baseline guidance for scheduling of vaccinations 
for these conditions and considerations regarding vaccination 
of special populations. ACIP recommendations are reviewed 
periodically and are revised as indicated when new information 
becomes available.
Corresponding preparer: Amy Parker Fiebelkorn, MSN, Division of 
Viral Diseases, National Center for Immunization and Respiratory 
Diseases, CDC. Telephone: 404-639-8235; E-mail: aparker@cdc.gov.
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Introduction
Measles, rubella, and mumps are acute viral diseases that 
can cause serious disease and complications of disease but 
can be prevented with vaccination. Vaccines for prevention of 
measles, rubella, and mumps were licensed and recommended 
for use in the United States in the 1960s and 1970s. Because 
of successful vaccination programs, measles, rubella, congenital 
rubella syndrome (CRS), and mumps are now uncommon in 
the United States. However, recent outbreaks of measles (1) 
and mumps (2,3) have occurred from import-associated cases 
because these diseases are common in many other countries. 
Persons who are unvaccinated put themselves and others at 
risk for these diseases and related complications.
Two live attenuated vaccines are licensed and available in 
the United States to prevent measles, mumps, and rubella: 
MMR vaccine (measles, mumps, and rubella [M-M-R II, 
Merck & Co., Inc.]), which is indicated routinely for persons 
aged ≥12 months and infants aged ≥6 months who are traveling 
internationally and MMRV vaccine (measles, mumps, rubella, 
and varicella [ProQuad, Merck & Co., Inc.]) licensed for 
children aged 12 months through 12 years. For the purposes 
of this report, MMR vaccine will be used as a general term 
for measles, mumps, and rubella vaccination; however, age-
appropriate use of either licensed vaccine formulation can be 
used to implement these vaccination recommendations. 
For the prevention of measles, mumps, and rubella, 
vaccination is recommended for persons aged ≥12 months. For 
the prevention of measles and mumps, ACIP recommends 2 
doses of MMR vaccine routinely for children with the first dose 
administered at age 12 through 15 months and the second dose 
administered at age 4 through 6 years before school entry. Two 
doses are recommended for adults at high risk for exposure and 
transmission (e.g., students attending colleges or other post-
high school educational institutions, health-care personnel, 
and international travelers) and 1 dose for other adults aged 
≥18 years. For prevention of rubella, 1 dose of MMR vaccine 
is recommended for persons aged ≥12 months. This report 
is a compendium of all current recommendations for the 
prevention of measles, rubella, congenital rubella syndrome 
(CRS), and mumps. The report presents the recent revisions 
adopted by the Advisory Committee on Immunization 
Practices (ACIP) on October 24, 2012, and also summarizes 
all existing ACIP recommendations that have been published 
previously during 1998–2011 (4–6). As a compendium of all 
current ACIP recommendations, the information in this report 
is intended for use by clinicians as guidance for scheduling of 
vaccinations for these conditions and considerations regarding 
vaccination of special populations.
Methods
Periodically, ACIP reviews available information to inform 
the development or revision of its vaccine recommendations. 
In May 2011, the ACIP measles, rubella, and mumps work 
group was formed to review and revise previously published 
vaccine recommendations. The work group held teleconference 
meetings monthly from May 2011 through October 2012. 
In addition to ACIP members, the work group included 
participants from the American Academy of Family Physicians 
(AAFP), the American Academy of Pediatrics (AAP), the 
American College Health Association, the Association of 
Immunization Managers, CDC, the Council of State and 
Territorial Epidemiologists, the Food and Drug Administration 
(FDA), the Infectious Diseases Society of America, the 
National Advisory Committee on Immunization (Canada), 
the National Institute of Health (NIH), and other infectious 
disease experts (7).*
Issues reviewed and considered by the work group included 
epidemiology of measles, rubella, CRS, and mumps in the 
United States; use of MMR vaccine among persons with 
HIV infection, specifically, revaccination of persons with 
perinatal HIV infection who were vaccinated before effective 
antiretroviral therapy (ART); use of a third dose of MMR vaccine 
for mumps outbreak control; timing of vaccine doses; use of 
immune globulin (IG) for measles postexposure prophylaxis; 
and vaccine safety. Recommendation options were developed 
and discussed by the work group. When evidence was lacking, 
the recommendations incorporated expert opinion of the work 
group members. Proposed revisions and a draft statement were 
presented to ACIP (ACIP meeting October 2011; February and 
June 2012) and approved at the October 2012 ACIP meeting. 
ACIP meeting minutes, including declaration of ACIP member 
conflicts of interest, if any, are available at http://www.cdc.gov/
vaccines/acip/meetings/meetings-info.html.
Background and Epidemiology 
of Measles
Measles (rubeola) is classified as a member of the genus 
Morbillivirus in the family Paramyxoviridae. Measles is a 
highly contagious rash illness that is transmitted from person 
to person by direct contact with respiratory droplets or 
airborne spread. After exposure, up to 90% of susceptible 
persons develop measles. The average incubation period for 
measles is 10 to 12 days from exposure to prodrome and 14 
days from exposure to rash (range: 7–21 days). Persons with 
measles are infectious 4 days before through 4 days after rash 
* A list of the work group appears on page 34.
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onset. In the United States, from 1987 to 2000, the most 
commonly reported complications associated with measles 
infection were pneumonia (6%), otitis media (7%), and 
diarrhea (8%) (8). For every 1,000 reported measles cases 
in the United States, approximately one case of encephalitis 
and two to three deaths resulted (9–11). The risk for death 
from measles or its complications is greater for infants, young 
children, and adults than for older children and adolescents. 
In low to middle income countries where malnutrition is 
common, measles is often more severe and the case-fatality 
ratio can be as high as 25% (12). In addition, measles can be 
severe and prolonged among immunocompromised persons, 
particularly those who have leukemias, lymphomas, or HIV 
infection (13–15). Among these persons, measles can occur 
without the typical rash and a patient can shed measles virus 
for several weeks after the acute illness (16–18). However, a 
fatal measles case without rash also has been reported in an 
apparently immunocompetent person (19).
Pregnant women also might be at high risk for severe 
measles and complications; however, available evidence does 
not support an association between measles in pregnancy and 
congenital defects (20). Measles illness in pregnancy might 
be associated with increased rates of spontaneous abortion, 
premature labor and preterm delivery, and low birthweight 
among affected infants (20–23).
A persistent measles virus infection can result in subacute 
sclerosing panencephalitis (SSPE), a rare and usually fatal neurologic 
degenerative disease. The risk for developing SSPE is 4–11 per 
100,000 measles cases (24,25), but can be higher when measles 
occurs among children aged <2 years (25,26). Signs and symptoms 
of SSPE appear an average of 7 years after measles infection, but 
might appear decades later (27). Widespread use of measles vaccine 
has led to the virtual disappearance of SSPE in the United States, but 
imported cases still occur (28). Available epidemiologic and virologic 
data indicate that measles vaccine virus does not cause SSPE (27). 
Wild type measles virus nucleotide sequences have been detected 
consistently from persons with SSPE who have reported vaccination 
and no history of natural infection (24,29–34).
Epidemiology of Measles during the 
Prevaccine Era
Before implementation of the national measles vaccination 
program in 1963, measles occurred in epidemic cycles and 
virtually every person acquired measles before adulthood (an 
estimated 3 to 4 million persons acquired measles each year). 
Approximately 500,000 persons with measles were reported 
each year in the United States, of whom 500 persons died, 
48,000 were hospitalized, and another 1,000 had permanent 
brain damage from measles encephalitis (28).
Epidemiology of Measles during the 
Vaccine Era
After the introduction of the 1-dose measles vaccination 
program, the number of reported measles cases decreased 
during the late 1960s and early 1970s to approximately 
22,000–75,000 cases per year (Figure 1) (35,36). Although 
measles incidence decreased substantially in all age groups, 
the greatest decrease occurred among children aged <10 
years. During 1984 through 1988, an average of 3,750 cases 
was reported each year (37). However, measles outbreaks 
among school-aged children who had received 1 dose of 
measles vaccine prompted ACIP in 1989 to recommend that 
all children receive 2 doses of measles-containing vaccine, 
preferably as MMR vaccine (38,39). The second dose of 
measles-containing vaccine primarily was intended to induce 
immunity in the small percentage of persons who did not 
seroconvert after vaccination with the first dose of vaccine 
(primary vaccine failure).
During 1989 through 1991, a major resurgence of measles 
occurred in the United States. Approximately 55,000 cases 
and 120 measles-related deaths were reported. The resurgence 
was characterized by an increasing proportion of cases 
among unvaccinated preschool-aged children, particularly 
among those residing in urban areas (40,41). Efforts to 
increase vaccination coverage among preschool-aged children 
emphasized vaccination as close to the recommended age as 
possible. To improve access to ACIP-recommended vaccines, 
the Vaccines for Children program, a federally funded program 
that provides vaccines at no cost to eligible persons aged <19 
years, was initiated in 1993 (42).
These efforts, combined with ongoing implementation 
of the 2-dose MMR vaccine recommendation, reduced 
reported measles cases to 309 in 1995 (43). During 1993, 
both epidemiologic and laboratory evidence suggested that 
transmission of indigenous measles had been interrupted in 
the United States (44,45).
The recommended measles vaccination schedule changed 
as knowledge of measles immunity increased and as the 
epidemiology of measles evolved within the United States. 
The recommended age for vaccination was 9 months in 1963, 
12 months in 1965, and 15 months in 1967. In 1989, because 
of reported measles outbreaks among vaccinated school-aged 
children, ACIP and AAFP recommended 2 doses; with the first 
dose at age 15 months and the second dose at age 4 through 6 
years, before school entry. In contrast, AAP had recommended 
administration of the second dose before middle school entry 
because outbreaks were occurring in older children, and to 
help reinforce the adolescent doctor’s visit and counteract 
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possible secondary vaccine failure (46). Since 1994, ages 
recommended by ACIP, AAFP, and AAP have been the same 
for the 2-dose MMR vaccine schedule; the first dose should be 
given to children aged 12 through 15 months and the second 
dose should be given to children aged 4 through 6 years (47).
Measles Elimination and Epidemiology 
during Postelimination Era
Because of the success of the measles vaccination program 
in achieving and maintaining high 1-dose MMR vaccine 
coverage in preschool-aged children, high 2-dose MMR vaccine 
coverage in school-aged children, and improved measles control 
in the World Health Organization (WHO) Region of the 
Americas, measles was documented and verified as eliminated 
from the United States in 2000 (48). Elimination is defined 
as the absence of endemic transmission (i.e., interruption 
of continuous transmission lasting ≥12 months). In 2002, 
measles was declared eliminated from the WHO Region of 
the Americas (49). 
Documenting and verifying the interruption of endemic 
transmission of the measles and rubella viruses in the Americas 
is ongoing in accordance with the Pan American Health 
Organization mandate of 2007 (http://www.paho.org/english/
gov/csp/csp27.r2-e.pdf ). An expert panel reviewed available 
data and unanimously agreed in December 2011 that measles 
elimination has been maintained in the United States (50,51). 
However, measles cases associated with importation of the virus 
from other countries continue to occur. From 2001 through 
2011, a median of 63 measles cases (range: 37–220) and four 
outbreaks, defined as three or more cases linked in time or place 
(range: 2–17), were reported each year in the United States. Of 
the 911 cases, a total of 372 (41%) cases were importations, 
804 (88%) were associated with importations, and 225 (25%) 
involved hospitalization. Two deaths were reported. Among 
the 162 cases reported from 2004 through 2008 among 
unvaccinated U.S. residents eligible for vaccination, a total 
of 110 (68%) were known to have occurred in persons who 
declined vaccination because of a philosophical, religious, or 
personal objection (52).
Background and Epidemiology of 
Rubella and Congenital Rubella 
Syndrome
Rubella (German measles) is classified as a Rubivirus in the 
Togaviridae family. Rubella is an illness transmitted through 
direct or droplet contact from nasopharyngeal secretions and 
is characterized by rash, low-grade fever, lymphadenopathy, 
and malaise. Symptoms are often mild and up to 50% of 
rubella infections are subclinical (53,54). However, among 
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Source: Measles data provided were reported voluntarily to CDC from state health departments.
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adults infected with rubella, transient arthralgia or arthritis 
occurs frequently, particularly among women (55). Other 
complications occur infrequently; thrombocytopenic purpura 
occurs in approximately one out of 3,000 cases and is more 
likely to involve children (56), and encephalitis occurs in 
approximately one out of 6,000 cases and is more likely to 
involve adults (57,58).
Rubella infection in pregnant women, especially during 
the first trimester, can result in miscarriages, stillbirths, and 
CRS, a constellation of birth defects that often includes 
cataracts, hearing loss, mental retardation, and congenital heart 
defects. In addition, infants with CRS frequently exhibit both 
intrauterine and postnatal growth retardation. Infants who are 
moderately or severely affected by CRS are readily recognizable 
at birth, but mild CRS (e.g., slight cardiac involvement or 
deafness) might not be detected for months or years after birth 
or not at all. The risk for congenital infection and defects is 
highest during the first 12 weeks of gestation (59–62), and the 
risk for any defect decreases after the 12th week of gestation. 
Defects are rare when infection occurs after the 20th week (63). 
Subclinical maternal rubella infection also can cause congenital 
malformations. Fetal infection without clinical signs of CRS 
can occur during any stage of pregnancy.
Rubella reinfection can occur and has been reported after 
both wild type rubella infection and after receiving 1 dose 
of rubella vaccine. Asymptomatic maternal reinfection in 
pregnancy has been considered to present minimal risk to the 
fetus (congenital infection in <10%) (64), but several isolated 
reports have been made of fetal infection and CRS among 
infants born to mothers who had documented serologic 
evidence of rubella immunity before they became pregnant 
and had reinfection during the first 12 weeks of gestation 
(64–68). CRS was not reported when reinfection occurred 
after 12 weeks gestation (69–71).
Epidemiology of Rubella and CRS during 
the Prevaccine Era
Before licensure of live, attenuated rubella vaccines in the 
United States in 1969, rubella was common, and epidemics 
occurred every 6 to 9 years (72). Most rubella cases were among 
young children, with peak incidence among children aged 5 
through 9 years (73). During the 1964 through 1965 rubella 
epidemic, an estimated 12.5 million rubella cases occurred in 
the United States, resulting in approximately 2,000 cases of 
encephalitis, 11,250 fetal deaths attributable to spontaneous 
or therapeutic abortions, 2,100 infants who were stillborn or 
died soon after birth, and 20,000 infants born with CRS (74).
Epidemiology of Rubella and CRS during 
the Vaccine Era
After introduction of rubella vaccines in the United States 
in 1969, reported rubella cases declined 78%, from 57,686 in 
1969 to 12,491 in 1976, and reported CRS cases declined by 
69%, from 68 in 1970 to 23 in 1976 (Figure 2) (73). Rubella 
incidence declined in all age groups, but children aged <15 
years experienced the greatest decline. Despite the declines, 
rubella outbreaks continued to occur among older adolescents 
and young adults and in settings where unvaccinated 
adults congregated. In 1977 and 1984, ACIP modified 
its recommendations to include vaccination of susceptible 
postpubertal females, adolescents, persons in military service, 
college students, and persons in certain work settings (75,76). 
The number of reported rubella cases decreased from 20,395 
in 1977 to 225 in 1988, and CRS cases decreased from 29 in 
1977 to 2 in 1988 (77).
During 1989 through 1991, a resurgence of rubella occurred, 
primarily because of outbreaks among unvaccinated adolescents 
and young adults who initially were not recommended for 
vaccination and in religious communities with low rubella 
vaccination coverage (77). As a result of the rubella outbreaks, 
two clusters of approximately 20 CRS cases occurred (78,79). 
Outbreaks during the mid-1990s occurred in settings where 
young adults congregated and involved unvaccinated persons 
who belonged to specific racial/ethnic groups (80). Further 
declines occurred as rubella vaccination efforts increased in 
other countries in the WHO Region of the Americas. From 
2001 through 2004, reported rubella and CRS cases were at 
an all-time low, with an average of 14 reported rubella cases 
a year, four CRS cases, and one rubella outbreak (defined as 
three or more cases linked in time or place) (81).
Rubella and CRS Elimination and 
Epidemiology during the 
Postelimination Era
In 2004, a panel convened by CDC reviewed available data 
and verified elimination of rubella in the United States (82). 
Rubella elimination is defined as the absence of endemic 
rubella transmission (i.e., continuous transmission lasting ≥12 
months). From 2005 through 2011, a median of 11 rubella cases 
was reported each year in the United States (range: 4–18). In 
addition, two rubella outbreaks involving three cases, as well as 
four total CRS cases, were reported. Among the 67 rubella cases 
reported from 2005 through 2011, a total of 28 (42%) cases 
were known importations (83; CDC, unpublished data, 2012).
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In 2010, on the basis of surveillance data, the Pan American 
Health Organization indicated that the WHO Region of 
the Americas had achieved the rubella and CRS elimination 
goals set in 2003 (84). Verification of maintenance of rubella 
elimination in the region is ongoing. However, an expert 
panel reviewed available data and unanimously agreed in 
December 2011 that rubella elimination has been maintained 
in the United States (50,51).
Background and Epidemiology 
of Mumps
Mumps virus is a member of the genus Rubulavirus in the 
Paramyxoviridae family. Mumps is an acute viral infection 
characterized by fever and inflammation of the salivary glands. 
Parotitis is the most common manifestation, with onset an 
average of 16 to 18 days after exposure (range: 12–25 days). In 
some studies, mumps symptoms were described as nonspecific 
or primarily respiratory; however, these reports based findings 
on serologic results taken every 6 or 12 months, making it 
difficult to prove whether the respiratory tract symptoms were 
caused by mumps virus infection or if the symptoms happened 
to occur at the same time as the mumps infection (85,86). In 
other studies conducted during the prevaccine era, 15%–27% 
of infections were described as asymptomatic (85,87,88). 
In the vaccine era, it is difficult to estimate the number of 
asymptomatic infections because the way vaccine modifies 
clinical presentation is unclear and only clinical cases with 
parotitis, other salivary gland involvement, or mumps-related 
complications are notifiable. Serious complications can occur 
in the absence of parotitis (89,90). Results from an outbreak 
from 2009 through 2010 indicated that complications are 
lower in vaccinated patients than with unvaccinated patients 
(6); however, during an outbreak in 2006, vaccination status 
was not significantly associated with complications (91). 
Persons with mumps are most infectious around the time of 
parotitis onset (92). Complications of mumps infection can 
vary with age and sex.
In the prevaccine era, orchitis was reported in 12%–66% of 
postpubertal males infected with mumps (93,94), compared 
with U.S. outbreaks in 2006 and 2009 through 2010 in the 
vaccine era, during which the range of rates of orchitis among 
postpubertal males was 3%–10% (91,95,96). In 60%–83% of 
males with mumps orchitis, only one testis is affected (87,90). 
Sterility from mumps orchitis, even bilateral orchitis, occurs 
infrequently (93).
In the prevaccine era among postpubertal women, oophoritis 
was reported in approximately 5% of postpubertal females 
affected with mumps (97,98). Mastitis was included in case 


































Source: Rubella and CRS data provided were reported voluntarily to CDC from state health departments.
* By year of birth.
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reports (99,100) but also was described in a 1956–1957 
outbreak as affecting 31% of postpubertal females (87). A 
significant association between prepubescent mumps in females 
and infertility has been reported; it has been suggested that 
oophoritis might have resulted in a disturbance of follicular 
maturation (101). In the vaccine era, among postpubertal 
females, the range of oophoritis rates was ≤1% (91,95,96) and 
the range of mastitis rates was ≤1% (91,95,96).
In the prevaccine era, pancreatitis was reported in 4% of 
342 persons infected with mumps in one community during a 
2-year period (85) and was described in case reports (102,103). 
Mumps also was a major cause of hearing loss among children 
in the prevaccine era, which could be sudden in onset, bilateral, 
or permanent hearing loss (104–106). In the prevaccine era, 
clinical aseptic meningitis occurred in 0.02%–10% of mumps 
cases and typically was mild (85,88,107–109). However, 
in exceedingly rare cases, mumps meningoencephalitis can 
cause permanent sequelae, including severe ataxia (110). The 
incidence of mumps encephalitis ranged from one in 6,000 
mumps cases (0.02%) (107) to one in 300 mumps cases (0.3%) 
in the prevaccine era (111). In the vaccine era, reported rates 
of pancreatitis, deafness, meningitis, and encephalitis were all 
<1% (91,95,96).
The average annual rate of hospitalization resulting from 
mumps during World War I was 55.8 per 1,000, which was 
exceeded only by the rates for influenza and gonorrhea (112). 
Mumps was a major cause of viral encephalitis, accounting 
for approximately 36% of encephalitis cases in 1967 (111). 
Death from mumps is exceedingly rare and is primarily caused 
by mumps-associated encephalitis (111). In the United States, 
from 1966 through 1971, two deaths occurred per 10,000 
reported mumps cases (111). Among vaccinated persons, 
severe complications of mumps are uncommon but occur 
more frequently among adults than children. No mumps-
related deaths were reported in the 2006 or the 2009–2010 
U.S. outbreaks (91,95,96).
Among pregnant women with mumps during the first 
trimester, an increased rate of spontaneous abortion or 
intrauterine fetal death has been observed in some studies; 
however, no evidence indicates that mumps causes birth defects 
(87,113–116).
Epidemiology of Mumps during the 
Prevaccine Era
Before the introduction of vaccine in 1967, mumps was a 
universal disease of childhood. Most children were infected by 
age 14 years, with peak incidence among children aged 5 through 
9 years (117,118). Outbreaks among the military were common, 
especially during times of mobilization (119,120).
Epidemiology of Mumps during the 
Vaccine Era
Reported cases of mumps decreased steadily after the 
introduction of live mumps vaccine in 1967 and the 
recommendation in 1977 for routine vaccination (Figure 3) 
(121). However, from 1986 through 1987, a resurgence of 
mumps occurred when a cohort not targeted for vaccination 
and spared from natural infection by declining disease rates 
entered high school and college, resulting in 20,638 reported 
cases (122,123). By the early 2000s, on average, fewer than 
270 cases were reported annually; a decrease of approximately 
99% from the 152,209 cases reported in 1968, and seasonal 
peaks were no longer present (124). In 2006, an outbreak of 
6,584 cases occurred and was centered among highly 2-dose 
vaccinated college students in the Midwestern United States 
(91). Children began receiving 2 doses of mumps vaccine after 
implementation of a 2-dose measles vaccination policy using 
MMR vaccine in 1989 (39). Nonetheless, ACIP specified 
in 2006 that all children and adults in certain high risk 
groups, including students at post-high school educational 
institutions, health-care personnel, and international travelers, 
should receive 2 doses of mumps-containing vaccine (3). 
From 2009 through 2010, mumps outbreaks occurred in a 
religious community in the Northeastern United States with 
approximately 3,500 cases and in the U.S. territory of Guam 
with 505 cases reported. Similar to the 2006 mumps outbreak, 
most patients had received 2 doses of MMR vaccine and were 
exposed in densely congregate settings (88,94). In 2011, a 
university campus in California reported 29 cases of mumps, of 
which 22 (76%) occurred among persons previously vaccinated 
with the recommended 2 doses of MMR vaccine (5).
Vaccines for Prevention of Measles, 
Rubella, and Mumps
Two combination vaccines are licensed and available in the 
United States to prevent measles, rubella, and mumps: trivalent 
MMR vaccine (measles-mumps-rubella [M-M-R II, Merck & 
Co., Inc.]) and quadrivalent MMRV vaccine (measles-mumps-
rubella-varicella [ProQuad, Merck &  Co., Inc.]). The efficacy 
and effectiveness of each component of the MMR vaccine is 
described below. MMRV vaccine was licensed on the basis 
of noninferior immunogenicity of the antigenic components 
compared with simultaneous administration of MMR vaccine 
and varicella vaccine (125). Formal studies to evaluate the 
clinical efficacy of MMRV vaccine have not been performed; 
efficacy of MMRV vaccine was inferred from that of MMR 
vaccine and varicella vaccine on the basis of noninferior 
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immunogenicity (126). Monovalent measles, rubella, and 
mumps vaccines and other vaccine combinations are no longer 
commercially available in the United States.
Measles Component
The measles component of the combination vaccines that 
are currently distributed in the United States was licensed in 
1968 and contains the live Enders-Edmonston (formerly called 
“Moraten”) vaccine strain. Enders-Edmonston vaccine strain 
is a further attenuated preparation of a previous vaccine strain 
(Edmonston B) that is grown in chick embryo cell culture. 
Because of increased efficacy and fewer adverse reactions, 
the vaccine containing the Enders-Edmonston vaccine strain 
replaced previous vaccines: inactivated Edmonston vaccine 
(available in the United States from 1963 through 1976), live 
attenuated vaccines containing the Edmonston B (available 
in the United States from 1963 through 1975), and Schwarz 
strain (available in the United States from 1965 through 1976).
Immune Response to Measles Vaccination
Measles-containing vaccines produce a subclinical  or mild, 
noncommunicable infection inducing both humoral and 
cellular immunity. Antibodies develop among approximately 
96% of children vaccinated at age 12 months with a single 
dose of the Enders-Edmonston vaccine strain (Table 1) 
(127–134). Almost all persons who do not respond to the 
measles component of the first dose of MMR vaccine at age 
≥12 months respond to the second dose (135,136).
Data on early measles vaccination suggest that infants 
vaccinated at age 6 months might have an age-related delay in 
maturation of humoral immune response to measles vaccine, 
unrelated to passively transferred maternal antibody, compared 
with infants vaccinated at age 9 or 12 months (137,138). 
However, markers of cell-mediated immune response to 
measles vaccine were equivalent when infants were vaccinated 
at age 6, 9, and 12 months, regardless of presence of passive 
antibodies (139).
Source: Mumps data provided were reported voluntarily to CDC from state health departments.
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Although the cell-mediated immune response to the first 
dose of measles vaccine alone might not be protective, it 
might prime the humoral response to the second dose (140). 
Data indicate that revaccination of children first vaccinated as 
early as age 6 months will result in vaccine-induced immunity, 
although the response might be associated with a lower 
antibody titer than titers of children vaccinated at age 9 or 12 
months (139).
Measles Vaccine Effectiveness
One dose of measles-containing vaccine administered at age 
≥12 months was approximately 94% effective in preventing 
measles (range: 39%–98%) in studies conducted in the 
WHO Region of the Americas (141,142). Measles outbreaks 
among populations that have received 2 doses of measles-
containing vaccine are uncommon. The effectiveness of 2 
doses of measles-containing vaccine was ≥99% in two studies 
conducted in the United States and 67%, 85%–≥94%, and 
100% in three studies in Canada (142–146). The range in 
2-dose vaccine effectiveness in the Canadian studies can be 
attributed to extremely small numbers (i.e., in the study with 
a 2-dose vaccine effectiveness of 67%, one 2-dose vaccinated 
person with measles and one unvaccinated person with 
measles were reported [145]). This range of effectiveness also 
can be attributed to age at vaccination (i.e., the 85% vaccine 
effectiveness represented children vaccinated at age 12 months, 
whereas the ≥94% vaccine effectiveness represented children 
vaccinated at age ≥15 months [146]). Furthermore, two studies 
found the incremental effectiveness of 2 doses was 89% and 
94%, compared with 1 dose of measles-containing vaccine 
(145,147). Similar estimates of vaccine effectiveness have been 
reported from Australia and Europe (Table 1) (141).
Duration of Measles Immunity after Vaccination
Both serologic and epidemiologic evidence indicate that 
measles-containing vaccines induce long lasting immunity 
in most persons (148). Approximately 95% of vaccinated 
persons examined 11 years after initial vaccination and 15 
years after the second dose of MMR (containing the Enders-
Edmonston strain) vaccine had detectable antibodies to 
measles (149–152). In one study among 25 age-appropriately 
vaccinated children aged 4 through 6 years who had both low-
level neutralizing antibodies and specific IgG antibodies by EIA 
before revaccination with MMR vaccine, 21 (84%) developed 
an anamnestic immune response upon revaccination; none 
developed IgM antibodies, indicating some level of immunity 
persisted (153).
Rubella Component
The rubella component of the combination vaccines that 
are currently distributed in the United States was licensed in 
1979 and contains the live Wistar RA 27/3 vaccine strain. The 
vaccine is prepared in human diploid cell culture and replaced 
previous vaccines (HPV-77 and Cendehill) because it induces a 
higher and more persistent antibody response and is associated 
with fewer adverse events (154–158).
Immune Response to Rubella Vaccination
Rubella vaccination induces both humoral and cellular 
immunity. Approximately 95% of susceptible persons aged 
≥12 months developed serologic evidence of immunity to 
rubella after vaccination with a single dose of rubella vaccine 
containing the RA 27/3 strain (Table 1) (127,154,157–164). 
After a second dose of MMR vaccine, approximately 99% 
had detectable rubella antibody and approximately 60% had 
a fourfold increase in titer (165–167).
Rubella Vaccine Effectiveness
Outbreaks of rubella in populations vaccinated with the 
rubella RA 27/3 vaccine strains are rare. Available studies 
demonstrate that vaccines containing the rubella RA 27/3 strain 
are approximately 97% effective in preventing clinical disease 
after a single dose (range: 94%–100%) (Table 1) (168–170).
TABLE 1. Summary of immune response (seroconversion), vaccine effectiveness, and duration of immunity for the measles, rubella, and mumps 
component of the MMR-II vaccine*
Disease
Seroconversion after 1 dose 
Median % (range)
Vaccine effectiveness median % (range) Duration of immunity
1 dose 2 doses 1 dose 2 doses
Measles† 96 (84–100) 93 (39–100) 97 (67–100) ≥11 years ≥15 years
Rubella§ 99 (95–100) 97 (94–100) NA ≥16 years ≥15 years
Mumps¶ 94    (89–97) 78    (49–92) 88   (66–95) ≥10 years ≥15 years
Abbreviation: NA = not applicable.
* Data were obtained from multiple studies describing immune response (seroconversion), vaccine effectiveness, and duration of immunity for the measles, rubella, 
and mumps component of the MMR-II vaccine.
† Data sources for measles: references 127–134 (for seroconversion), 141–146 (for vaccine effectiveness), and 148–152 (for duration of immunity).
§ Data sources for rubella: references 127, 154, 157–164 (for seroconversion), 168–170 (for vaccine effectiveness), and 150, 165, 171–174 (for duration of immunity).
¶ Data sources for mumps: references 127, 157, 176–184 (for seroconversion), 199–210 (for vaccine effectiveness), and 150 and 187–189 (for duration of immunity).  
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Duration of Rubella Immunity after Vaccination
Follow-up studies indicate that 1 dose of rubella vaccine 
can provide long lasting immunity. The majority of persons 
had detectable rubella antibodies up to 16 years after 1 dose 
of rubella-containing vaccine, but antibody levels decreased 
over time (165,171–174). Although levels of vaccine-induced 
rubella antibodies might decrease over time, data from 
surveillance of rubella and CRS suggest that waning immunity 
with increased susceptibility to rubella disease does not occur. 
Among persons with 2 doses, approximately 91%–100% had 
detectable antibodies 12 to 15 years after receiving the second 
dose (150,165).
Mumps Component
The mumps component of the vaccine available in the 
United States contains the live attenuated mumps Jeryl-Lynn 
vaccine strain. It was developed using an isolate from a child 
with mumps and passaged in embryonated hens’ eggs and chick 
embryo cell cultures (175). The vaccine produces a subclinical, 
noncommunicable infection with very few side effects.
Immune Response to Mumps Vaccination
Approximately 94% of infants and children develop 
detectable mumps antibodies after vaccination with MMR 
vaccine (range: 89%–97%) (Table 1) (127,157,176–184). 
However, vaccination induces relatively low levels of antibodies 
compared with natural infection (185,186). Among persons 
who received a second dose of MMR vaccine, most mounted 
a secondary immune response, approximately 50% had a 
fourfold increase in antibody titers, and the proportion with 
low or undetectable titers was significantly reduced from 20% 
before vaccination with a second dose to 4% at 6 months post 
vaccination (187–189). Although antibody measurements 
are often used as a surrogate measure of immunity, no 
serologic tests are available for mumps that consistently and 
reliably predict immunity. The immune response to mumps 
vaccination probably involves both the humoral and cellular 
immune response, but no definitive correlates of protection 
have been identified.
Mumps Vaccine Effectiveness
Clinical studies conducted before vaccine licensure in 
approximately 7,000 children found a single dose of mumps 
vaccine to be approximately 95% effective in preventing 
mumps disease (186,190,191). However, vaccine effectiveness 
estimates have been lower in postlicensure studies. In the 
United States, mumps vaccine effectiveness has been estimated 
to be between 81% and 91% in junior high and high school 
settings (192–197), and between 64% and 76% among 
household or close contacts for 1 dose of mumps-containing 
vaccine (196,198). Population and school-based studies 
conducted in Europe and Canada report comparable estimates 
for vaccine effectiveness (49%–92%) (199–210).
Fewer studies have been conducted to assess the effectiveness 
of 2 doses of mumps-containing vaccine. In the United States, 
outbreaks among populations with high 2-dose coverage found 
2 doses of mumps-containing vaccine to be 80%–92% effective 
in preventing clinical disease (198,211). In the 1988 through 
1989 outbreak among junior high school students, the risk 
for mumps was five times higher for students who received 
1 dose compared with students who received 2 doses (195). 
Population and school-based studies in Europe and Canada 
estimate 2 doses of mumps-containing vaccine to be 66%–95% 
effective (Table 1) (201–204,208–210). Despite relatively high 
2-dose vaccine effectiveness, high 2-dose vaccine coverage 
might not be sufficient to prevent all outbreaks (6,91,212).
Duration of Mumps Immunity after Vaccination
Studies indicate that 1 dose of MMR vaccine can provide 
persistent antibodies to mumps. The majority of persons 
(70%–99%) examined approximately 10 years after initial 
vaccination had detectable mumps antibodies (187–189). In 
addition, 70% of adults who were vaccinated in childhood 
had T-lymphocyte immunity to mumps compared with 
80% of adults who acquired natural infection in childhood 
(213). Similarly, in 2-dose recipients, mumps antibodies were 
detectable in the majority of persons (74%–95%) followed over 
12 years after receipt of a second dose of MMR vaccine, but 
antibody levels declined with time (150,187). Among vaccine 
recipients who do not have detectable mumps antibodies, 
mumps antigen-specific lymphoproliferative responses have 
been detected, but their role in protection against mumps 
disease is not clear (214,215).
Effectiveness of MMR Vaccine as Measles 
Postexposure Prophylaxis
For measles, evidence of the effectiveness of MMR or measles 
vaccine administered as postexposure prophylaxis is limited 
and mixed (216–222). Effectiveness might depend on timing 
of vaccination and the nature of the exposure. If administered 
within 72 hours of initial measles exposure, MMR vaccine 
might provide some protection against infection or modify 
the clinical course of disease (216–219,222).
Several published studies have compared attack rates among 
persons who received MMR or single antigen measles vaccine 
(without gamma globulin) as postexposure prophylaxis with 
those who remained unvaccinated after exposure to measles. 
Postexposure prophylaxis with MMR vaccine appears to be 
effective if the vaccine is administered within 3 days of exposure 
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to measles in “limited” contact settings (e.g., schools, childcare, 
and medical offices) (218,222). Postexposure prophylaxis does 
not appear to be effective in settings with intense, prolonged, 
close contact, such as households and smaller childcare facilities, 
even when the dose is administered within 72 hours of rash 
onset, because persons in these settings are often exposed for 
long durations during the prodromal period when the index 
patient is infectious (219–221). However, these household 
studies are limited by number of persons receiving post-exposure 
prophylaxis (i.e., less than 10 persons were given MMR vaccine 
as postexposure prophylaxis within 72 hours of rash onset in 
each of the cited studies) (219–221). Revaccination within 72 
hours of exposure of those who have received 1 dose before 
exposure also might prevent disease (223). For rubella and 
mumps, postexposure MMR vaccination has not been shown 
to prevent or alter the clinical severity of disease.
Use of Third Dose MMR Vaccine for Mumps 
Outbreak Control
Data on use and effectiveness of a third dose of MMR 
vaccine for mumps outbreak control are limited. A study 
among a small number of seronegative college students who 
had 2 documented doses of MMR vaccine demonstrated that 
a third dose of MMR vaccine resulted in a rapid mumps virus 
IgG response. Of 17 participants, a total of 14 (82%) were 
IgG positive at 7–10 days after revaccination, suggesting that 
previously vaccinated persons administered a third dose of 
MMR vaccine had the capacity to mount a rapid anamnestic 
immune response that could possibly boost immunity to 
protective levels (224). In 2010, in collaboration with local 
health departments, CDC conducted two Institutional Review 
Board (IRB)-approved studies to evaluate the effect of a third 
dose of MMR vaccine during mumps outbreaks in highly 
vaccinated populations in Orange County, New York (>94% 
2-dose coverage among 2,688 students attending private school 
in grades 6 through12) and Guam (≥95% 2-dose coverage 
among 3,364 students attending public primary and middle 
school in grades 4 through 8).
In Orange County, New York, a total of 1,755 (81%) eligible 
students in grades 6 through 12 (ages 11 through 17 years) 
in three schools received a third dose of MMR vaccine as part 
of the study (95). Overall attack rates declined 76% in the 
village after the intervention, with the greatest decline among 
those aged 11 through 17 years targeted for vaccination (with 
a significant decline of 96% postintervention compared with 
preintervention). The 96% decline in attack rates in this age 
group was significantly greater than the declines in other age 
groups that did not receive the third dose intervention (95). 
However, the intervention was conducted after the outbreak 
started to decline. Because of the high rate of vaccine uptake 
and small number of cases observed in the 22–42 days 
after vaccination, the study could not directly evaluate the 
effectiveness of a third dose.
During a mumps outbreak in Guam in 2010, a total of 
3,239 eligible children aged 9 through 14 years in seven 
schools were offered a third dose of MMR vaccine (96). Of 
the eligible children, 1,067 (33%) received a third dose of 
MMR vaccine. More than one incubation period after the 
third dose intervention, students who had 3 doses of MMR 
vaccine had a 2.6-fold lower mumps attack rate compared with 
students who had 2 doses of MMR vaccine (0.9 per 1,000 
versus 2.4 per 1,000), but the difference was not statistically 
significant (Relative Risk [RR] = 0.40, 95% Confidence 
interval [CI] = 0.05–3.4, p = 0.67). The intervention was 
conducted after the outbreak started to decline and during 
the week before the end of the school year, which limited the 
ability to evaluate effectiveness of the intervention.
Data are insufficient to recommend for or against the use 
of a third dose of MMR vaccine for mumps outbreak control. 
CDC has issued guidance for consideration for use of a third 
dose in specifically identified target populations along with 
criteria for public health departments to consider for decision 
making (http://www.cdc.gov/vaccines/pubs/surv-manual/
chpt09-mumps.html).
Immune Response to MMR Vaccine among 
Persons with HIV Infection
Before the availability of effective ART, responses to MMR 
vaccine among persons with HIV infection were suboptimal. 
Although response to revaccination varied, it generally was poor 
(225,226). In addition, measles antibodies appear to decline 
more rapidly in children with HIV infection than in children 
without HIV infection (227,228).
Memory B cell counts and function appear to be normal in 
HIV-infected children who are started on effective ART early 
(aged <1 year), and responses to measles and rubella vaccination 
appear to be adequate. Measles antibody titers were higher 
in HIV-infected children who started effective ART early 
compared with HIV-infected children who started effective 
ART later in life (229). Likewise, vaccinated HIV-infected 
children who initiated effective ART before vaccination had 
rubella antibody responses similar to those observed in HIV-
uninfected children (230).
Despite evidence of immune reconstitution, effective ART 
does not appear to reliably restore immunity from previous 
vaccinations. Perinatally HIV-infected youth who received 
MMR vaccine before effective ART might have increased 
susceptibility to measles, mumps, and rubella compared 
with HIV-exposed but uninfected persons. Approximately 
45%–65% of previously vaccinated HIV-infected children 
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had detectable antibodies to measles after initiation of effective 
ART, 55%–80% had detectable antibodies to rubella, and 
52%–59% had detectable antibodies to mumps (231–235). 
However, revaccination with MMR vaccine after initiation 
of effective ART increased the proportion of HIV-infected 
children with detectable antibodies to measles, rubella, and 
mumps (64%–90% for measles, 80%–100% for rubella, and 
78% for mumps) (230,234,236–240). Although, data on 
duration of response to revaccination on effective ART are 
limited, the majority of children had detectable antibodies to 
measles (73%–85%), rubella (79%), and mumps (61%) 1–4 
years after revaccination (234,238,240).
Vaccine Dosage, Administration, 
and Storage
The lyophilized live MMR vaccine and MMRV vaccine 
should be reconstituted and administered as recommended 
by the manufacturer (241,242). Both vaccines available in 
the United States should be administered subcutaneously. 
Although both vaccines must be protected from light, which 
might inactivate the vaccine viruses, the two vaccines have 
different storage requirements (Table 2). Administration of 
improperly stored vaccine might fail to provide protection 
against disease. The diluent can be stored in the refrigerator 
or at room temperature but should not be allowed to freeze.
MMR Vaccine
MMR vaccine is supplied in lyophilized form and must be 
stored at −50°C to 8°C (−58°F to 46°F) and protected from 
light at all times. The vaccine in the lyophilized form can be 
stored in the freezer. Reconstituted MMR vaccine should be 
used immediately or stored in a dark place at 2°C to 8°C (36°F 
to 46°F) for up to 8 hours and should not be frozen or exposed 
to freezing temperatures (241).
MMRV Vaccine
MMRV vaccine is supplied in a lyophilized frozen form 
that should be stored at −50°C to -15°C (−58°F to 5°F) in a 
reliable freezer. Reconstituted vaccine can be stored at room 
temperature between 20°C to 25°C (68°F to 77°F), protected 
from light for up to 30 minutes. Reconstituted MMRV vaccine 
must be discarded if not used within 30 minutes and should 
not be frozen (242).
Contraindications and Precautions
Before administering MMR or MMRV vaccine, providers 
should consult the package insert for precautions, warnings, 
and contraindications (241,242).
Contraindications
Contraindications for MMR and MMRV vaccines include 
history of anaphylactic reactions to neomycin, history of severe 
allergic reaction to any component of the vaccine, pregnancy, 
and immunosuppression.
History of anaphylactic reactions to neomycin. MMR 
and MMRV vaccine contain trace amounts of neomycin; 
therefore, persons who have experienced anaphylactic reactions 
to topically or systemically administered neomycin should 
not receive these vaccines. However, neomycin allergy usually 
manifests as a delayed type or cell-mediated immune response 
(i.e., a contact dermatitis) rather than as anaphylaxis. In persons 
who have such sensitivity, the adverse reaction to the neomycin 
in the vaccine is an erythematous, pruritic nodule or papule 
appearing 48–72 hours after vaccination (243). A history of 
contact dermatitis to neomycin is not a contraindication to 
receiving MMR-containing vaccine.
History of severe allergic reaction to any component 
of the vaccine. MMR and MMRV vaccine should not be 
administered to persons who have experienced severe allergic 
reactions to a previous dose of measles-, mumps-, rubella-, 
TABLE 2. Storage requirements for measles, mumps, and rubella (MMR) and measles, mumps, rubella, and varicella (MMRV) vaccines*
Form MMR vaccine MMRV vaccine
Lyophilized form Vaccine should be shipped and stored at -50°C to +8°C 
(-58°F to +46°F) to maintain potency.
Do not use dry ice because this may subject the vaccine to 
temperatures colder than -50°C (-58°F).
Vaccine should be shipped at -50°C to -15°C (-58°F to +5°F).
Do not use dry ice because temperatures below -50°C 
(-58°F) might reduce potency.
Reconstituted form Use reconstituted vaccine as soon as possible or store at 
2°C to 8°C (36°F to 46°F) for up to 8 hours.
Discard if not used.
Use reconstituted vaccine as soon as possible or store at 
room temperature for up to 30 minutes.
Discard if not used.
Diluent Store at room temperature 20°C to 25°C (68°F to 77°F) or 
in a refrigerator 2°C to 8°C (36°F to 46°F). 
Do not freeze.
Store at room temperature 20°C to 25°C (68°F to 77°F) or 
in a refrigerator 2°C to 8°C (36°F to 46°F). 
Do not freeze.
* Vaccine viruses can be inactivated by light and should always be stored in a dark place.
Recommendations and Reports
MMWR / June 14, 2013 / Vol. 62 / No. 4 13
or varicella (for MMRV vaccine)-containing vaccine or 
to a vaccine component. Although measles and mumps 
components of the vaccine are grown in chick embryo 
fibroblast tissue culture, allergy to egg is not a contraindication 
to vaccination. Among persons who are allergic to eggs, the 
risk for serious allergic reactions, such as anaphylaxis after 
administration of MMR vaccine, is exceedingly low (i.e., at 
least 99% of children with challenge-proved egg allergy can 
receive this vaccine in one subcutaneous dose without severe 
anaphylactic reactions [CI = 99%–100%]) (244). Skin testing 
with vaccine is not predictive of allergic reaction to vaccination 
(244–246). Therefore, skin testing is not required before 
administering MMR or MMRV vaccines to persons who are 
allergic to eggs. The rare serious allergic reactions after measles 
or mumps vaccination or MMR vaccination are not believed 
to be caused by egg antigens, but by other components of the 
vaccine (247–249)
Pregnancy. MMR vaccines should not be administered 
to women known to be pregnant or attempting to become 
pregnant. Because of the theoretical risk to the fetus when 
the mother receives a live virus vaccine, women should be 
counseled to avoid becoming pregnant for 28 days after 
receipt of MMR vaccine (2). If the vaccine is inadvertently 
administered to a pregnant woman or a pregnancy occurs 
within 28 days of vaccination, she should be counseled about 
the theoretical risk to the fetus. The theoretical maximum risk 
for CRS after the administration of rubella RA 27/3 vaccine on 
the basis of the 95% CI of the binomial distribution with 144 
observations in one study was estimated to be 2.6%, and the 
observed risk was 0% (250). Other reports have documented 
no cases of CRS among approximately 1,000 live-born infants 
of susceptible women who were vaccinated inadvertently with 
the rubella RA 27/3 vaccine while pregnant or just before 
conception (251–257). Of these, approximately 100 women 
were known to be vaccinated within 1 week before to 4 weeks 
after conception (251,252), the period presumed to be the 
highest risk for viremia and fetal malformations. These figures 
are considerably lower than the ≥20% risk associated with wild 
rubella virus infection of mothers during the first trimester of 
pregnancy with wild rubella virus or the risk for non-CRS-
induced congenital defects in pregnancy (250). Thus, MMR 
vaccination during pregnancy should not be considered an 
indication for termination of pregnancy.
MMR vaccine can be administered safely to children or other 
persons without evidence of immunity to measles, mumps, 
or rubella and who have pregnant household contacts to help 
protect these pregnant women from exposure to wild rubella 
virus. No reports of transmission of measles or mumps vaccine 
virus exist from vaccine recipients to susceptible contacts; 
although small amounts of rubella vaccine virus are detected 
in the noses or throats of most rubella susceptible persons 7 
to 28 days post-vaccination, no documented confirmed cases 
of transmission of rubella vaccine virus have been reported.
Immunosuppression. MMR and MMRV vaccine should 
not be administered to 1) persons with primary or acquired 
immunodeficiency, including persons with immunosuppres-
sion associated with cellular immunodeficiencies, hypogam-
maglobulinemia, dysgammaglobulinemia and AIDS or severe 
immunosuppression associated with HIV infection; 2) persons 
with blood dyscrasias, leukemia, lymphomas of any type, or 
other malignant neoplasms affecting the bone marrow or 
lymphatic system; 3) persons who have a family history of 
congenital or hereditary immunodeficiency in first-degree 
relatives (e.g., parents and siblings), unless the immune compe-
tence of the potential vaccine recipient has been substantiated 
clinically or verified by a laboratory; or 4) persons receiving 
systemic immunosuppressive therapy, including corticosteroids 
≥2 mg/kg of body weight or ≥20 mg/day of prednisone or 
equivalent for persons who weigh >10 kg, when administered 
for ≥2 weeks (258). Persons with HIV infection who do not 
have severe immunosuppression should receive MMR vaccine, 
but not MMRV vaccine (see subsection titled Persons with 
HIV Infection). Measles inclusion body encephalitis has been 
reported after administration of MMR vaccine to immunosup-
pressed persons, as well as after natural measles infection with 
wild type virus (see section titled Safety of MMR and MMRV 
Vaccines) (259–261).
Precautions
Precautions for MMR and MMRV vaccines include recent 
(≤11 months) receipt of an antibody-containing blood product, 
concurrent moderate or severe illness with or without fever, 
history of thrombocytopenia or thrombocytopenic purpura, 
and tuberculin skin testing. If a tuberculin test is to be 
performed, it should be administered either any time before, 
simultaneously with, or at least 4–6 weeks after administration 
of MMR or MMRV vaccine. An additional precaution for 
MMRV vaccine includes persons with a personal or family 
history of seizures of any etiology.
Recent (≤11 months) receipt of antibody-containing blood 
product. Receipt of antibody-containing blood products (e.g., 
IG, whole blood, or packed red blood cells) might interfere 
with the serologic response to measles and rubella vaccine for 
variable periods, depending on the dose of IG administered 
(262). The effect of IG-containing preparations on the response 
to mumps vaccine is unknown.
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MMR vaccine should be administered to persons who have 
received an IG preparation only after the recommended intervals 
have elapsed (258). However, postpartum administration of 
MMR vaccine to women who lack presumptive evidence 
of immunity to rubella should not be delayed because anti-
Rho(D) IG (human) or any other blood product were received 
during the last trimester of pregnancy or at delivery. These 
women should be vaccinated immediately after delivery 
and tested at least 3 months later to ensure that they have 
presumptive evidence of immunity to rubella and measles.
Moderate or severe illness with or without fever. Vaccination 
of persons with concurrent moderate or severe illness, including 
untreated, active tuberculosis, should be deferred until they have 
recovered. This precaution avoids superimposing any adverse 
effects of the vaccine on the underlying illness or mistakenly 
attributing a manifestation of the underlying illness to the 
vaccine. The decision to vaccinate or postpone vaccination 
depends largely on the cause of the illness and the severity of 
symptoms. MMR vaccine can be administered to children who 
have mild illness, with or without low-grade fever, including 
mild upper respiratory infections, diarrhea, and otitis media. 
Data indicate that seroconversion is not affected by concurrent 
or recent mild illness (263–265). Physicians should be alert to 
the vaccine-associated temperature elevations that might occur 
predominately in the second week after vaccination, especially 
with the first dose of MMRV vaccine.
Persons being treated for tuberculosis have not experienced 
exacerbations of the disease when vaccinated with MMR 
vaccine. Although no studies have been reported concerning the 
effect of MMR or MMRV vaccines on persons with untreated 
tuberculosis, a theoretical basis exists for concern that measles 
vaccine might exacerbate tuberculosis. Consequently, before 
administering MMR vaccine to persons with untreated active 
tuberculosis, initiating antituberculous therapy is advisable. 
Testing for latent tuberculosis infection is not a prerequisite 
for routine vaccination with MMR vaccine.
History of thrombocytopenia or thrombocytopenic 
purpura. Persons who have a history of thrombocytopenia 
or thrombocytopenic purpura might be at increased risk 
for developing clinically significant thrombocytopenia after 
MMR or MMRV vaccination. Persons with a history of 
thrombocytopenia have experienced recurrences after MMR 
vaccination (266,267), whereas others have not had a repeat 
episode after MMR vaccination (268–270). In addition, 
persons who developed thrombocytopenia with a previous 
dose might develop thrombocytopenia with a subsequent dose 
of MMR vaccine (271,272). However, among 33 children 
who were admitted for idiopathic thrombocytopenic purpura 
before receipt of a second dose of MMR vaccine, none had a 
recurrence within 6 weeks of the second MMR vaccine (273). 
Serologic evidence of immunity can be sought to determine 
whether or not an additional dose of MMR or MMRV vaccine 
is needed.
Tuberculin testing. MMR vaccine might interfere with the 
response to a tuberculin skin test, resulting in a temporary 
depression of tuberculin skin sensitivity (274–276). Therefore, 
if a tuberculin skin test is to be performed, it should be 
administered either any time before, simultaneously with, or 
at least 4–6 weeks after MMR or MMRV vaccine. As with 
the tuberculin skin tests, live virus vaccines also might affect 
tuberculosis interferon-gamma release assay (IGRAs) test 
results. However, the effect of live virus vaccination on IGRAs 
has not been studied. Until additional information is available, 
IGRA testing in the context of live virus vaccine administration 
should be done either on the same day as vaccination with 
live-virus vaccine or 4–6 weeks after the administration of the 
live-virus vaccine.
Personal or family history of seizures of any etiology. A 
personal or family (i.e., sibling or parent) history of seizures 
of any etiology is a precaution for the first dose of MMRV but 
not MMR vaccination. Studies suggest that children who have 
a personal or family history of febrile seizures or family history 
of epilepsy are at increased risk for febrile seizures compared 
with children without such histories. In one study, the risk dif-
ference of febrile seizure within 14 days of MMR vaccination 
for children aged 15 to 17 months with a personal history of 
febrile seizures was 19.5 per 1,000 (CI = 16.1– 23.6) and for 
siblings of children with a history of febrile seizures was four 
per 1,000 (CI = 2.9–5.4) compared with unvaccinated children 
of the same age (277). In another study, the match adjusted 
odds ratio for children with a family history of febrile seizures 
was 4.8 (CI = 1.3–18.6) compared with children without a 
family history of febrile seizures (278). For the first dose of 
measles vaccine, children with a personal or family history of 
seizures of any etiology generally should be vaccinated with 
MMR vaccine because the risks for using MMRV vaccine in 
this group of children generally outweigh the benefits.
Safety of MMR and MMRV Vaccine
Adverse Events and Other Conditions 
Reported after Vaccination with MMR or 
MMRV Vaccine
MMR vaccine generally is well-tolerated and rarely associated 
with serious adverse events. MMR vaccine might cause fever 
(<15%), transient rashes (5%), transient lymphadenopathy 
(5% of children and 20% of adults), or parotitis (<1%) 
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(160,163,279–283). Febrile reactions usually occur 7–12 
days after vaccination and generally last 1–2 days (280). The 
majority of persons with fever are otherwise asymptomatic. Four 
adverse events (i.e., coryza, cough, pharyngitis, and headache) 
after revaccination were found to be significantly lower with 
a second dose of MMR vaccine, and six adverse events (i.e., 
conjunctivitis, nausea, vomiting, lymphadenopathy, joint pain, 
and swollen jaw) had no significant change compared with the 
prevaccination baseline in school-aged children (284).
Expert committees at the Institute of Medicine (IOM) 
reviewed evidence concerning the causal relation between 
MMR vaccination and various adverse events (285–289). 
Their causality was assessed on the basis of epidemiologic 
evidence derived from studies of populations, as well as 
mechanistic evidence derived primarily from biologic and 
clinical studies in animals and humans; risk was not quantified. 
IOM determined that evidence supports a causal relation 
between MMR vaccination and anaphylaxis, febrile seizures, 
thrombocytopenic purpura, transient arthralgia, and measles 
inclusion body encephalitis in persons with demonstrated 
immunodeficiencies.
Anaphylaxis. Immediate anaphylactic reactions after MMR 
vaccination are rare (1.8–14.4 per million doses) (290–293). 
Although measles- and mumps-containing vaccines are grown 
in tissue from chick embryos, the rare serious allergic reactions 
after MMR vaccination are not believed to be caused by egg 
antigens but by other components of the vaccine, such as 
gelatin or neomycin (247–249).
Febrile seizures. MMR vaccination might cause febrile 
seizures. The risk for such seizures is approximately one case 
for every 3,000 to 4,000 doses of MMR vaccine administered 
(294,295). Children with a personal or family history of febrile 
seizures or family history of epilepsy might be at increased risk 
for febrile seizures after MMR vaccination (277,278). The febrile 
seizures typically occur 6–14 days after vaccination and do not 
appear to be associated with any long-term sequelae (294–297). 
An approximate twofold increased risk exists for febrile seizures 
among children aged 12 to 23 months who received the first 
dose of MMRV vaccine compared with children who received 
MMR and varicella vaccines separately. One additional febrile 
seizure occurred 5 through 12 days after vaccination per 2,300 
to 2,600 children who received the first dose of MMRV vaccine 
compared with children who received the first dose of MMR and 
varicella vaccine separately but at the same visit (298,299). No 
increased risk for febrile seizures was observed after vaccination 
with MMRV vaccine in children aged 4 through 6 years (300). 
For additional details, see ACIP recommendations on the use 
of combination MMRV vaccine (126).
Thrombocytopenic purpura. Immune thrombocytopenic 
purpura (ITP), a disorder affecting blood platelet count, 
might be idiopathic or associated with a number of viral 
infections. ITP after receipt of live attenuated measles 
vaccine and wild type measles infections is usually self-limited 
and not life threatening; however, complications of ITP 
might include severe bleeding requiring blood transfusion 
(267,268,270). The risk for ITP increases during the 6 weeks 
after MMR vaccination, with one study estimating one case 
per 40,000 doses (270). The risk for thrombocytopenia after 
MMR vaccination is much less than after natural infection 
with rubella (one case per 3,000 infections) (56). On the 
basis of case reports, the risk for MMR vaccine-associated 
thrombocytopenia might be increased for persons who 
previously have had ITP (see Precautions).
Arthralgia and arthritis. Joint symptoms are associated with 
the rubella component of MMR vaccine (301). Among persons 
without rubella immunity who receive rubella-containing 
vaccine, arthralgia and transient arthritis occur more frequently 
among adults than children, and more frequently among 
postpubertal females than males (302,303). Acute arthralgia 
or arthritis are rare among children who receive RA 27/3 
vaccine (160,303). In contrast, arthralgia develops among 
approximately 25% of nonimmune postpubertal females after 
vaccination with rubella RA 27/3 vaccine, and approximately 
10% to 30% have acute arthritis-like signs and symptoms 
(154,160,282,301). Arthralgia or arthritis generally begin 1–3 
weeks after vaccination, usually are mild and not incapacitating, 
lasts about 2 days, and rarely recur (160,301,303,304).
Measles inclusion body encephalitis. Measles inclusion 
body encephalitis is a complication of measles infection that 
occurs in young persons with defective cellular immunity from 
either congenital or acquired causes. The complications develop 
within 1 year after initial measles infection and the mortality 
rate is high. Three published reports in persons with immune 
deficiencies described measles inclusion body encephalitis after 
measles vaccination, documented by intranuclear inclusions 
corresponding to measles virus or the isolation of measles virus 
from the brain among vaccinated persons (259–261,289). The 
time from vaccination to development of measles inclusion 
body encephalitis for these cases was 4–9 months, consistent 
with development of measles inclusion body encephalitis after 
infection with wild measles virus (305). In one case, the measles 
vaccine strain was identified (260).
Other possible adverse events. IOM concluded that the 
body of evidence favors rejection of a causal association between 
MMR vaccine and risk for autistic spectrum disorders (ASD), 
including autism, inflammatory bowel diseases, and type 1 
diabetes mellitus. In addition, the available evidence was not 
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adequate to accept or reject a causal relation between MMR 
vaccine and the following conditions: acute disseminated 
encephalomyelitis, afebrile seizures, brachial neuritis, chronic 
arthralgia, chronic arthritis, chronic fatigue syndrome, chronic 
inflammatory disseminated polyneuropathy, encephalopathy, 
fibromyalgia, Guillain-Barré syndrome, hearing loss, hepatitis, 
meningitis, multiple sclerosis, neuromyelitis optica, optic 
neuritis, transverse myelitis, opsoclonus myoclonus syndrome, 
or radiculoneuritis and other neuropathies.
Adverse Events after Administration of a 
Third Dose of MMR Vaccine
Short-term safety of administration of a third dose of MMR 
vaccine was evaluated following vaccination clinics during two 
mumps outbreaks among 2,130 persons aged 9 through 21 
years (96,306). Although these studies did not include a control 
group, few adverse events were reported after administration 
of a third dose of MMR vaccine (7% in Orange County, New 
York and 6% in Guam). The most commonly reported adverse 
events were pain, redness, or swelling at the injection site 
(2%–4%); joint or muscle aches (2%–3%); and dizziness or 
lightheadedness (2%). No serious adverse events were reported 
in either study.
Safety of MMR Vaccine among Persons 
with HIV Infection
HIV-infected persons are at increased risk for severe 
complications if infected with measles (16,307–310), and 
several severe and fatal measles cases have been reported in 
HIV-infected children after vaccination, including progressive 
measles pneumonitis in a person with HIV infection and 
severe immunosuppression who received MMR vaccine 
(311), and several deaths after measles vaccination among 
persons with severe immunosuppression unrelated to HIV 
infection (312–314). No serious or unusual adverse events 
have been reported after measles vaccination among persons 
with HIV infection who did not have evidence of severe 
immunosuppression (315–320). Severe immunosuppression 
is defined as CD4+ T-lymphocyte percentages <15% at any 
age or CD4 count <200 lymphocytes/mm3 for persons aged 
>5 years (321,322). Furthermore, no serious adverse events 
have been reported in several studies in which MMR vaccine 
was administered to a small number of children on ART with 
histories of immunosuppression (231,233,238). MMR vaccine 
is not recommended for persons with HIV infection who have 
evidence of severe immunosuppression, and MMRV vaccine 
is not approved for use in any persons with HIV infection.
Reporting of Vaccine Adverse Events
Clinically significant adverse events that arise after 
vaccination should be reported to the Vaccine Adverse Event 
Reporting System (VAERS) at http://vaers.hhs.gov/esub/
index. VAERS is a postmarketing safety surveillance program 
that collects information about adverse events (possible side 
effects) that occur after the administration of vaccines licensed 
for use in the United States.
 Reports can be filed securely online, by mail, or by fax. A 
VAERS form can be downloaded from the VAERS website or 
requested by e-mail (info@vaers.org), telephone (800-822-7967), 
or fax (877-721-0366). Additional information on VAERS or 
vaccine safety is available at http://vaers.hhs.gov/about/index or 
by calling telephone 800-822-7967.
National Vaccine Injury 
Compensation Program
The National Vaccine Injury Compensation Program 
(VICP), established by the National Childhood Vaccine Injury 
Act (NCVIA) of 1986, as amended, provides a mechanism 
through which compensation can be paid on behalf of a person 
determined to have been injured or to have died as a result of 
receiving a vaccine covered by VICP (323). NCVIA requires 
health-care providers to report any adverse events listed by the 
manufacturer as a contraindication to further vaccine or any 
adverse event listed in the VAERS Table of Reportable Events 
Following Vaccination that occurs within the specified time 
period after vaccination (324). The Vaccine Injury Table lists 
the vaccines covered by VICP and the injuries and conditions 
(including death) for which compensation might be paid. If 
the injury or condition is not included in the table, or does not 
occur within the specified time period on the table, persons 
must prove that the vaccine caused the injury or condition. 
For a person to be eligible for compensation, the general filing 
deadlines for injuries require claims to be filed within 3 years 
after the first symptom of the vaccine injury; for a death, claims 
must be filed within 2 years of the vaccine-related death and 
not more than 4 years after the start of the first symptom of 
the vaccine-related injury from which the death occurred. 
When a new vaccine is covered by VICP or when a new injury/
condition is added to the table, claims that do not meet the 
general filing deadlines must be filed within 2 years from the 
date the vaccine or injury/condition is added to the table for 
injuries or deaths that occurred up to 8 years before the table 
change. Persons who receive a VICP-covered vaccine might be 
eligible to file a claim. Additional information about VICP is 
available at http://www.hrsa.gov/vaccinecompensation/index.
html or by calling 800–338–2382.
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Immune Globulin for Prevention 
of Measles
Immune Globulin Products
Human immune globulin (IG) is a blood product used to 
provide antibodies for short-term prevention of infectious 
diseases, including measles. IG products are prepared from 
plasma pools derived from thousands of donors. Persons who 
have measles disease typically have higher measles antibody 
titers than persons who have vaccine-induced measles 
immunity. Although the prevalence of measles antibodies is 
high in the U.S. population (325), potency of IG products 
has declined as a result of change in the donor population 
from persons with immunity from disease to persons with 
predominately vaccine-induced measles immunity (326).
Multiple IG preparations are available in the United 
States and include IG administered intramuscularly (IGIM), 
intravenously (IGIV), and subcutaneously (IGSC). The 
minimum measles antibody potency requirement for IGIM 
used in the United States is 0.60 of the reference standard (U.S. 
Reference IG, Lot 176) and 0.48 of the reference standard for 
IGIV and IGSC. In 2007, the FDA Blood Products Advisory 
Committee lowered the measles antibody concentration 
requirements for IGIV and IGSC from 0.60 to 0.48 of the 
reference standard when testing and calculations indicated 
that IGIV and IGSC products with this minimum potency 
could be expected to provide a measles antibody concentration 
of ≥120 mIU/mL, the estimated protective level of measles 
neutralizing antibody (327), for 28–30 days, if administered 
at the minimum label recommended dose of 200 mg/kg (328).
Historically, IGIM has been the blood product of choice 
for short-term measles prophylaxis and was the product used 
to demonstrate efficacy for measles postexposure prophylaxis 
(329). The recommended dose of IGIM is 0.5mL/kg. Because 
concentrations of antibodies are lower, an increase in dose is 
needed. However, postexposure use of IGIM might be limited 
because of volume limitations. The maximum dose by volume 
is 15 mL. Persons who weigh >30 kg will receive less than the 
recommended dose and will have lower titers than recommended.
IGIV has been available since 1981 and is used primarily for 
the prevention of common infectious diseases for patients with 
primary immunodeficiency disorders. Although a larger dose 
can be administered with IGIV compared with IGIM, clinical 
use of IGIV has important disadvantages, including high cost 
and administration requiring extended observation in specialized 
settings by skilled professionals (i.e., hospital setting).
IGSC has been available since 2006 with the same major 
indication as IGIV. However, administration requires a pump 
and advanced training. Also, multiple, consecutive weekly 
doses are needed to establish a steady-state with protective 
antibody levels.




htm. One IGIM product is licensed and available in the 
United States, and the package insert is available at http://
www.talecris-pi.info/inserts/gamastans-d.pdf.
Effectiveness of Postexposure Prophylaxis 
with IGIM
IGIM has been used as prophylaxis to prevent or attenuate 
measles disease since the 1940s, when it was demonstrated 
that IGIM can reduce the risk for measles or modify disease if 
administered within 6 days of exposure (329,330) with a dose 
response effect (331). However, postexposure IGIM was not 
effective in a study conducted in 1990 (220). Although the 
optimal dose of IGIM needed to provide protection against 
measles infection after exposure is unknown, a study from 
1999 through 2000 indicated a titer-dependent effect, with 
higher antimeasles titer providing the greatest protection (332). 
Children who did not develop disease received a mean dose of 
10.9 IU/kg compared with 5.7 IU/kg for children in which 
postexposure prophylaxis with IGIM failed.
Measles Susceptibility in Infants
Infants typically are protected from measles at birth by 
passively acquired maternal antibodies. The duration of 
this protection depends largely on the amount of antibody 
transferred, which is related to gestational age and maternal 
antibody titer (333). Women with vaccine-derived measles 
immunity have lower antibody titers and transfer shorter 
term protection than women who have had measles disease 
(333–335). Although foreign-born mothers accounted for 23% 
of all births in 2010 and most of these mothers born outside 
the Western Hemisphere likely had immunity from wild 
measles (336), the majority of women of childbearing age in 
the United States now have vaccine-derived measles immunity. 
Fewer opportunities exist for boosting this immunity by 
exposure to wild type viruses. Thus, infants born now are 
more likely to be susceptible to measles at a younger age 
(337). Seroepidemiologic studies indicate that 7% of infants 
born in the United States might lack antimeasles antibodies 
at birth and up to 90% of infants might be seronegative by 
age 6 months (139,325). These data suggest a change in the 
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window of vulnerability for measles infection during infancy, a 
strong need to preserve herd protection, vigilance for imported 
cases, and rapid access to IG products when postexposure 
prophylaxis is needed.
Evidence of Immunity
The criteria for acceptable evidence of measles, rubella, 
and mumps immunity were developed to guide vaccination 
assessment and administration in clinical and public health 
settings and to provide presumptive rather than absolute 
evidence of immunity. Persons who meet the criteria for 
acceptable evidence of immunity have a very high likelihood 
of immunity. Occasionally, a person who meets the criteria for 
presumptive immunity can acquire and transmit disease. Specific 
criteria for documentation of immunity have been established 
for measles, rubella, and mumps (Table 3). These criteria apply 
only to routine vaccination. During outbreaks, recommended 
criteria for presumptive evidence of immunity might differ 
for some groups (see section titled Recommendations during 
Outbreaks of Measles, Rubella, or Mumps).
Vaccine doses with written documentation of the date of 
administration at age ≥12 months are the only doses considered 
to be valid. Self-reported doses and history of vaccination 
provided by a parent or other caregiver are not considered 
adequate evidence of immunity. Because of the extremely 
low incidence of these diseases in the United States, the 
validity of clinical diagnosis of measles, rubella, and mumps 
is questionable and should not be considered in assessing 
evidence. Persons who do not have documentation of adequate 
vaccination or other acceptable evidence of immunity (Table 3) 
should be vaccinated.
Serologic screening for measles, rubella, or mumps immunity 
before vaccination is not necessary and not recommended if 
a person has other acceptable evidence of immunity to these 
diseases (Table 3). Similarly, postvaccination serologic testing 
to verify an immune response is not recommended.
Documented age-appropriate vaccination supersedes 
the results of subsequent serologic testing. If a person who 
has 2 documented doses of measles- or mumps-containing 
vaccines is tested serologically and is determined to have 
negative or equivocal measles or mumps titer results, it is 
not recommended that the person receive an additional dose 
of MMR vaccine. Such persons should be considered to 
have presumptive evidence of immunity. In the event that a 
person who has 1 dose of rubella-containing vaccine is tested 
serologically and is determined to have negative or equivocal 
rubella titer results, it is not recommended that the person 
receive an additional dose of MMR vaccine, except for women 
of childbearing age. Women of childbearing age who have 1 
or 2 documented doses of rubella-containing vaccine and have 
rubella-specific IgG levels that are not clearly positive should be 
administered 1 additional dose of MMR vaccine (maximum of 
3 doses) and do not need to be retested for serologic evidence 
of rubella immunity.
Evidence of Measles Immunity
Persons who have documentation of adequate vaccination 
for measles at age ≥12 months, laboratory evidence of measles 
immunity, laboratory confirmation of disease, or were born 
before 1957 have acceptable presumptive evidence of measles 
immunity (Table 3). Adequate vaccination for measles for 
preschool-aged children (i.e., aged ≥12 months) and adults not 
at high risk for exposure or transmission is documentation of 
vaccination with at least 1 dose of live measles virus-containing 
vaccine. For school-aged children in kindergarten through 
grade 12, students at post-high school educational institutions, 
health-care personnel, and international travelers, adequate 
vaccination for measles is documentation of vaccination with 
2 doses of live measles virus-containing vaccine separated by 
at least 28 days. Adequate vaccination for measles for infants 
aged 6 through 11 months before international travel is 1 dose 
of live measles virus-containing vaccine.
Persons who have measles-specific IgG antibody that is 
detectable by any commonly used serologic assay are considered 
to have adequate laboratory evidence of measles immunity. 
Persons with an equivocal serologic test result do not have 
adequate presumptive evidence of immunity and should be 
considered susceptible, unless they have other evidence of 
measles immunity (Table 3) or subsequent testing indicates 
measles immunity.
Evidence of Rubella Immunity
Persons who have documentation of vaccination with 
at least 1 dose of live rubella virus-containing vaccine at 
age ≥12 months, laboratory evidence of rubella immunity, 
laboratory confirmation of disease, or were born before 1957 
(except women who could become pregnant) have acceptable 
presumptive evidence of rubella immunity (Table 3). Birth 
before 1957 is not acceptable evidence of rubella immunity for 
women who could become pregnant. Documented evidence of 
rubella immunity is important for women who could become 
pregnant because rubella can occur among some unvaccinated 
persons born before 1957 and congenital rubella and CRS can 
occur among the offspring of women infected with rubella 
during pregnancy.
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TABLE 3. Acceptable presumptive evidence of immunity to measles, rubella, and mumps* 
Routine
Students at post-high school 
educational institutions Health-care personnel† International travelers
Measles (1) Documentation of age-
appropriate vaccination with a 





(grades K-12): 2 doses  
–adults not at high risk¶¶: 
1 dose, or
(2) Laboratory evidence of 
immunity,¶ or
(3) Laboratory confirmation of 
disease, or
(4) Born before 1957
(1) Documentation of vaccination 
with 2 doses of live measles 
virus-containing vaccine,§ or
(2) Laboratory evidence of 
immunity,¶ or 
(3) Laboratory confirmation of 
disease, or
(4) Born before 1957
(1) Documentation of vaccination 
with 2 doses of live measles 
virus-containing vaccine,§ or
(2) Laboratory evidence of 
immunity,¶ or 
(3) Laboratory confirmation of 
disease, or
(4) Born before 1957††
(1) Documentation of age-
appropriate vaccination with a 
live measles virus-containing 
vaccine: 
–infants aged 6–11 months**: 
1 dose 
–persons aged ≥12 months§: 
2 doses, or 
(2) Laboratory evidence of 
immunity,¶ or 
(3) Laboratory confirmation of 
disease, or
(4) Born before 1957
Rubella (1) Documentation of vaccination 
with 1 dose of live rubella 
virus-containing vaccine,§ or
(2) Laboratory evidence of 
immunity,¶ or
(3) Laboratory confirmation of 
disease, or
(4) Born before 1957 (except 
women of childbearing 
age who could become 
pregnant§§)
(1) Documentation of vaccination 
with 1 dose of live rubella 
virus-containing vaccine,§ or
(2) Laboratory evidence of 
immunity,¶ or 
(3) Laboratory confirmation of 
disease, or
(4) Born before 1957 (except 
women of childbearing 
age who could become 
pregnant§§)
(1) Documentation of vaccination 
with 1 dose of live rubella 
virus-containing vaccine,§ or
(2) Laboratory evidence of 
immunity,¶ or 
(3) Laboratory confirmation of 
disease, or
(4) Born before 1957†† (except 
women of childbearing 
age who could become 
pregnant§§)
(1) Documentation of vaccination 
with 1 dose of live rubella 
virus-containing vaccine,§ or
(2) Laboratory evidence of 
immunity,¶ or 
(3) Laboratory confirmation of 
disease, or
(4) Born before 1957 (except 
women of childbearing 
age who could become 
pregnant§§)
Mumps (1) Documentation of age-
appropriate vaccination with 





(grades K–12): 2 doses 
–adults not at high risk¶¶: 
1 dose, or
(2) Laboratory evidence of 
immunity,¶ or
(3) Laboratory confirmation of 
disease, or 
(4) Born before 1957
(1) Documentation of vaccination 
with 2 doses of live mumps 
virus-containing vaccine§, or
(2) Laboratory evidence of 
immunity,¶ or 
(3) Laboratory confirmation of 
disease, or
(4) Born before 1957 
(1) Documentation of vaccination 
with 2 doses of live mumps 
virus-containing vaccine,§ or
(2) Laboratory evidence of 
immunity,¶ or 
(3) Laboratory confirmation of 
disease, or
(4) Born before 1957†† 
(1) Documented administration of 
2 doses of live mumps virus-
containing vaccine,§ or
(2) Laboratory evidence of 
immunity,¶ or 
(3) Laboratory confirmation of 
disease, or
(4) Born before 1957 
 * Can vary depending on current state or local requirements.
 † Health-care personnel include all paid and unpaid persons working in health-care settings who have the potential for exposure to patients and/or to infectious 
materials, including body substances, contaminated medical supplies and equipment, contaminated environmental surfaces, or contaminated air. 
 § The first dose of MMR vaccine should be administered at age ≥12 months; the second dose of measles- or mumps-containing vaccine should be administered no 
earlier than 28 days after the first dose. 
 ¶ Measles, rubella, or mumps immunoglobulin G (IgG) in serum; equivocal results should be considered negative.
 ** Children who receive a dose of MMR vaccine at age <12 months should be revaccinated with 2 doses of MMR vaccine, the first of which should be administered 
when the child is aged 12 through 15 months and the second at least 28 days later. If the child remains in an area where disease risk is high, the first dose should 
be administered at age 12 months.
 †† For unvaccinated personnel born before 1957 who lack laboratory evidence of measles, rubella, or mumps immunity or laboratory confirmation of disease, health-
care facilities should consider vaccinating personnel with 2 doses of MMR vaccine at the appropriate interval (for measles and mumps) and 1 dose of MMR vaccine 
(for rubella), respectively. 
 §§ Women of childbearing age are adolescent girls and premenopausal adult women. Because rubella can occur in some persons born before 1957 and because 
congenital rubella and congenital rubella syndrome can occur in the offspring of women infected with rubella virus during pregnancy, birth before 1957 is not 
acceptable evidence of rubella immunity for women who could become pregnant. 
 ¶¶ Adults at high risk include students in post-high school educational institutions, health-care personnel, and international travelers. 
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Persons who have rubella-specific antibody levels above the 
standard positive cutoff value for the assay can be considered to 
have adequate evidence of rubella immunity. Except for women 
of childbearing age, persons who have an equivocal serologic 
test result should be considered susceptible to rubella unless 
they have documented receipt of 1 dose of rubella-containing 
vaccine or subsequent serologic test results indicate rubella 
immunity. Vaccinated women of childbearing age who have 
received 1 or 2 doses of rubella-containing vaccine and have 
rubella serum IgG levels that are not clearly positive should be 
administered 1 additional dose of MMR vaccine (maximum of 
3 doses) and do not need to be retested for serologic evidence 
of rubella immunity.
Evidence of Mumps Immunity
Persons who have written documentation of adequate 
vaccination for mumps at age ≥12 months, laboratory evidence 
of mumps immunity, laboratory confirmation of disease, or 
were born before 1957 have acceptable presumptive evidence of 
mumps immunity (Table 3). Adequate vaccination for mumps 
for preschool-aged children (i.e., aged ≥12 months) and adults 
not at high risk for exposure or transmission is documentation of 
vaccination with at least 1 dose of live mumps virus-containing 
vaccine. For children in kindergarten through grade 12, 
students at post-high school educational institutions, health-
care personnel, and international travelers, adequate vaccination 
for mumps is documentation of 2 doses of live mumps virus-
containing vaccine separated by at least 28 days.
Persons who have mumps-specific IgG antibody that is 
detectable by any commonly used serologic assay are considered 
to have adequate laboratory evidence of mumps immunity. 
Persons who have an equivocal serologic test result should 
be considered susceptible to mumps unless they have other 
evidence of mumps immunity (Table 3) or subsequent testing 
indicates mumps immunity.
Rationale for Measles, Rubella, and 
Mumps Vaccination
Safe and effective vaccines for prevention of measles, rubella, 
and mumps have been available in the United States for 
more than 40 years. Before availability of vaccines, measles, 
rubella, and mumps were common diseases in childhood and 
caused significant morbidity and mortality. As a result of the 
routine vaccination program, measles and rubella elimination 
(interruption of endemic transmission chains up to 1 year in 
length) was achieved in the United States in 2000 and 2004, 
respectively, and the number of mumps cases has decreased 
by approximately 99% (48,82,124). In December 2011, an 
expert panel reviewed available evidence and agreed that the 
United States has maintained elimination of measles and 
rubella (50,51). Furthermore, an economic analysis found that 
the 2-dose MMR vaccination program in the United States 
resulted in a substantial cost savings (approximately $3.5 billion 
and $7.6 billion from the direct cost and societal perspectives, 
respectively) and high benefit-cost ratios: for every dollar spent, 
the program saves approximately $14 of direct costs and $10 
of additional productivity costs (on the basis of estimates using 
2001 U.S. dollars) (338).
Despite the success in eliminating and maintaining 
elimination of endemic transmission of measles and rubella in 
the United States, the significant decline in mumps morbidity 
in the United States, and the considerable progress achieved 
in global measles and rubella control, measles, rubella, CRS, 
and mumps are still common diseases in many countries. 
Importations will continue to occur and cause outbreaks 
in communities that have clusters of unvaccinated persons. 
Persons who remain unvaccinated put themselves and others in 
their community, particularly those who cannot be vaccinated, 
at risk for these diseases and their complications. High levels 
of population immunity through vaccination are needed to 
prevent large outbreaks and maintain measles and rubella 
elimination and low mumps incidence in the United States.
Recommendations for Vaccination 
for Measles, Rubella, and Mumps
Measles, rubella, and mumps vaccines are recommended for 
prevention of measles, rubella, and mumps. For prevention of 
measles and mumps, 1 dose is recommended for preschool-
aged children aged ≥12 months and adults not at high risk for 
exposure and transmission, and 2 doses are recommended for 
school-aged children in kindergarten through grade 12 and 
adults at high risk for exposure and transmission (e.g., students 
attending colleges or other post-high school educational 
institutions, health-care personnel, and international travelers). 
For prevention of rubella, 1 dose is recommended for persons 
aged ≥12 months. Either MMR vaccine or MMRV vaccine 
can be used to implement the vaccination recommendations 
for prevention of measles, mumps, and rubella (126). MMR 
vaccine is indicated for persons aged ≥12 months. MMRV 
vaccine is licensed for use only in children aged 12 months 
through 12 years. The minimum interval between the 2 doses 
of MMR vaccine or MMR vaccine and MMRV vaccine is 
28 days, with the first dose administered at age ≥12 months. 
The minimum interval between 2 doses of MMRV vaccine 
is 3 months.
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ACIP recommends that for the first dose of measles, mumps, 
rubella, and varicella vaccines at age 12 through 47 months 
either MMR vaccine and varicella vaccine or MMRV vaccine 
can be used. Providers who are considering administering 
MMRV vaccine should discuss the benefits of and risks for 
both vaccination options with the parents or caregivers. Unless 
the parent or caregiver expresses a preference for MMRV 
vaccine, CDC recommends that MMR vaccine and varicella 
vaccines be administered for the first dose in this age group 
because of the increased risk for febrile seizures 5 through 12 
days after vaccination with MMRV vaccine compared with 
MMR vaccine among children aged 12 through 23 months 
(126,298,299).
For the second dose at any age (15 months through 12 years) 
and the first dose at age 48 months through 12 years, use of 
MMRV vaccine generally is preferred as opposed to separate 
injections of its equivalent component vaccines (MMR vaccine 
and varicella vaccine). Considerations for using separate 
injections instead of MMRV vaccine should include provider 
assessment (i.e., the number of injections, vaccine availability, 
likelihood of improved coverage, likelihood of patient return, 
and storage and cost considerations), patient preference, and 
potential adverse events (see ACIP recommendations on use 
of combination MMRV vaccine) (126).
Routine Vaccination of Persons Aged 
12 Months to 18 Years
Preschool-Aged Children (Aged ≥12 Months)
All eligible children should receive the first dose of MMR 
vaccine routinely at age 12 through 15 months. Vaccination 
with MMR vaccine is recommended for all children as soon 
as possible upon reaching age 12 months.
School-Aged Children (Grades Kindergarten 
through 12)
The second dose of MMR vaccine is recommended routinely 
for all children aged 4 through 6 years before entering 
kindergarten or first grade. However, the second dose of MMR 
vaccine can be administered at an earlier age if the interval 
between the first and second dose is more than 28 days.
Vaccination of Adults (Aged ≥18 Years)
Adults born in 1957 or later should receive at least 1 dose of 
MMR vaccine unless they have other acceptable evidence of 
immunity to these three diseases (Table 3). However, persons 
who received measles vaccine of unknown type, inactivated 
measles vaccine, or further attenuated measles vaccine 
accompanied by IG or high-titer measles immune globulin 
(no longer available in the United States) should be considered 
unvaccinated and should be revaccinated with 1 or 2 doses of 
MMR vaccine. Persons vaccinated before 1979 with either 
killed mumps vaccine or mumps vaccine of unknown type 
who are at high risk for mumps infection (e.g., persons who 
are working in a health-care facility) should be considered for 
revaccination with 2 doses of MMR vaccine.
Adults born before 1957 can be considered to have 
immunity to measles, rubella (except for women who could 
become pregnant), and mumps. However, MMR vaccine 
(1 dose or 2 doses administered at least 28 days apart) can be 
administered to any person born before 1957 who does not 
have a contraindication to MMR vaccination.
Adults who might be at increased risk for exposure or 
transmission of measles, rubella, or mumps and who do not 
have evidence of immunity should receive special consideration 
for vaccination. Students attending colleges or other post-high 
school educational institutions, health-care personnel, and 
international travelers should receive 2 doses of MMR vaccine.
Vaccination of Special Populations
School-Aged Children, College Students, and 
Students in Other Postsecondary Educational 
Institutions
All students entering school, colleges, universities, technical 
and vocational schools, and other institutions for post-high 
school education should receive 2 doses of MMR vaccine (with 
the first dose administered at age ≥12 months) or have other 
evidence of measles, rubella, and mumps immunity (Table 3) 
before enrollment. Students who have already received 2 
appropriately spaced doses of MMR vaccine do not need an 
additional dose when they enter school.
Health-Care Personnel
To prevent disease and transmission in health-care settings, 
health-care institutions should ensure that all persons who work in 
health-care facilities have documentation of adequate vaccination 
against measles, rubella, and mumps or other acceptable evidence 
of immunity to these diseases (Table 3) (6).
Health-Care Personnel Born During or After 1957
Adequate vaccination for health-care personnel born  during 
or after 1957 consists of 2 doses of live measles virus-containing 
vaccine, 2 doses of live mumps virus-containing vaccine, and at 
least 1 dose of a live rubella virus-containing vaccine (Table 3). 
The second dose of live measles virus-containing or mumps 
virus-containing vaccine should be administered at least 28 days 
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after their first dose. Health-care facilities should use secure, 
preferably computerized, systems to manage vaccination records 
for health-care personnel so records can be retrieved easily (6).
Health-Care Personnel Born Before 1957
Although birth before 1957 is considered acceptable evidence 
of measles, rubella, and mumps immunity, health-care facilities 
should consider vaccinating unvaccinated personnel born 
before 1957 who do not have laboratory evidence of measles, 
rubella, and mumps immunity; laboratory confirmation of 
disease; or vaccination with 2 appropriately spaced doses of 
MMR vaccine for measles and mumps and 1 dose of MMR 
vaccine for rubella. Vaccination recommendations during 
outbreaks differ from routine recommendations for this group 
(see section titled Recommendations during Outbreaks of 
Measles, Rubella, or Mumps).
Serologic Testing of Health-Care Personnel
Prevaccination antibody screening before measles, rubella, 
or mumps vaccination for health-care personnel who do 
not have adequate presumptive evidence of immunity is not 
necessary unless the medical facility considers it cost effective. 
For health-care personnel who have 2 documented doses of 
measles- and mumps- containing vaccine and 1 documented 
dose of rubella-containing vaccine or other acceptable evidence 
of measles, rubella, and mumps immunity, serologic testing for 
immunity is not recommended. If health-care personnel who 
have 2 documented doses of measles- or mumps- containing 
vaccine are tested serologically and have negative or equivocal 
titer results for measles or mumps, it is not recommended that 
they receive an additional dose of MMR vaccine. Such persons 
should be considered to have acceptable evidence of measles 
and mumps immunity; retesting is not necessary. Similarly, if 
health-care personnel (except for women of childbearing age) 
who have one documented dose of rubella-containing vaccine 
are tested serologically and have negative or equivocal titer 
results for rubella, it is not recommended that they receive 
an additional dose of MMR vaccine. Such persons should be 
considered to have acceptable evidence of rubella immunity.
International Travelers Aged ≥6 Months
Measles, rubella, and mumps are endemic in many countries 
and protection against measles, rubella, and mumps is 
important before international travel. All persons aged ≥6 
months who plan to travel or live abroad should ensure that 
they have acceptable evidence of immunity to measles, rubella, 
and mumps before travel (Table 3). Travelers aged ≥6 months 
who do not have acceptable evidence of measles, rubella, and 
mumps immunity should be vaccinated with MMR vaccine. 
Before departure from the United States, children aged 6 
through 11 months should receive 1 dose of MMR vaccine and 
children aged ≥12 months and adults should receive 2 doses of 
MMR vaccine separated by at least 28 days, with the first dose 
administered at age ≥12 months. Children who received MMR 
vaccine before age 12 months should be considered potentially 
susceptible to all three diseases and should be revaccinated with 
2 doses of MMR vaccine, the first dose administered when the 
child is aged 12 through 15 months (12 months if the child 
remains in an area where disease risk is high) and the second 
dose at least 28 days later.
Women of Childbearing Age
All women of childbearing age (i.e., adolescent girls and 
premenopausal adult women), especially those who grew 
up outside the United States in areas where routine rubella 
vaccination might not occur, should be vaccinated with 1 dose 
of MMR vaccine or have other acceptable evidence of rubella 
immunity. Nonpregnant women of childbearing age who 
do not have documentation of rubella vaccination, serologic 
evidence of rubella immunity, or laboratory confirmation of 
rubella disease should be vaccinated with MMR vaccine. Birth 
before 1957 is not acceptable evidence of rubella immunity 
for women who could become pregnant. Women known to be 
pregnant should not receive MMR vaccine. Upon completion 
or termination of their pregnancies, women who do not have 
evidence of rubella immunity should be vaccinated before 
discharge from the health-care facility. Women should be 
counseled to avoid becoming pregnant for 28 days after 
administration of MMR vaccine.
Prenatal serologic screening is indicated for all pregnant 
women who lack acceptable evidence of rubella immunity 
(Table 3). Sera sent for screening for immunity should be 
tested for rubella IgG antibodies only and not for rubella 
IgM antibodies, unless a suspicion exists of recent rubella 
exposure (i.e., contact with a person suspected or confirmed 
to have contracted rubella). Testing for rubella IgM might lead 
to detection of nonspecific IgM, resulting in a false positive 
test result and long-persisting IgM results that are difficult to 
interpret (339).
Household and Close Contacts of 
Immunocompromised Persons
Immunocompromised persons are at high risk for severe 
complications if infected with measles. All family and other 
close contacts of immunocompromised persons aged ≥12 
months should receive 2 doses of MMR vaccine unless they 
have other evidence of measles immunity (Table 3).
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Persons with Human Immunodeficiency Virus (HIV) 
Infection
Vaccination of Persons with HIV Infection Who Do Not 
Have Current Evidence of Severe Immunosuppression
Two doses of MMR vaccine are recommended for all 
persons aged ≥12 months with HIV infection who do not 
have evidence of measles, rubella, and mumps immunity or 
evidence of severe immunosuppression. Absence of severe 
immunosuppression is defined as CD4 percentages ≥15% for 
≥6 months for persons aged ≤5 years and CD4 percentages 
≥15% and CD4 count ≥200 lymphocytes/mm3 for ≥6 months 
for persons aged >5 years. When only CD4 counts or CD4 
percentages are available for those aged >5 years, the assessment 
of severe immunosuppression can be on the basis of the 
CD4 values (count or percentage) that are available. When 
CD4 percentages are not available for those aged ≤5 years, 
the assessment of severe immunosuppression can be on the 
basis of age-specific CD4 counts at the time CD4 counts 
were measured (i.e., absence of severe immunosuppression is 
defined as ≥6 months above age-specific CD4 count criteria: 
CD4 count >750 lymphocytes/mm3 while aged ≤12 months 
and CD4 count ≥500 lymphocytes/mm3 while aged 1 through 
5 years).
The first dose of MMR vaccine should be administered at age 
12 through 15 months and the second dose at age 4 through 6 
years, or as early as 28 days after the first dose. Older children 
and adults with newly diagnosed HIV infections and without 
acceptable evidence of measles, rubella, or mumps immunity 
(Table 3) should complete a 2-dose schedule with MMR vaccine 
as soon as possible after diagnosis, unless they have evidence of 
severe immunosuppression (i.e., CD4 percentage <15% [all ages] 
or CD4 count <200 lymphocytes/mm3 [aged >5 years]). MMRV 
vaccine has not been studied in persons with HIV infection and 
should not be substituted for MMR vaccine.
Revaccination of Persons with Perinatal HIV Infection 
Who Do Not Have Evidence of Severe 
Immunosuppression
Persons with perinatal HIV infection who were vaccinated 
with measles-, rubella-, or mumps-containing vaccine 
before establishment of effective ART should receive 2 
appropriately spaced doses of MMR vaccine (i.e., 1 dose 
now and another dose at least 28 days later) once effective 
ART has been established unless they have other acceptable 
current evidence of measles, rubella, and mumps immunity 
(Table 3). Established effective ART is defined as receiving 
ART for ≥6 months in combination with CD4 percentages 
≥15% for ≥6 months for persons aged ≤5 years and CD4 
percentages ≥15% and CD4 count ≥200 lymphocytes/mm3 
for ≥6 months for persons aged >5 years. When only CD4 
counts or only CD4 percentages are available for those aged 
>5 years, the assessment of established effective ART can be 
on the basis of the CD4 values (count or percentage) that are 
available. When CD4 percentages are not available for those 
aged ≤5 years, the assessment of established effective ART can 
be on the basis of age-specific CD4 counts at the time CD4 
counts were measured (i.e., established effective ART is defined 
as receiving ART for ≥6 months in combination with meeting 
age-specific CD4 count criteria for ≥6 months: CD4 count 
>750 lymphocytes/mm3 while aged ≤12 months and CD4 
count ≥500 lymphocytes/mm3 while aged 1 through 5 years).
Recommendations during Outbreaks 
of Measles, Rubella, or Mumps
During measles, rubella, or mumps outbreaks, efforts should 
be made to ensure that all persons at risk for exposure and 
infection are vaccinated or have other acceptable evidence of 
immunity (Table 3). Evidence of adequate vaccination for 
school-aged children, college students, and students in other 
postsecondary educational institutions who are at risk for 
exposure and infection during measles and mumps outbreaks 
consists of 2 doses of measles- or mumps-containing vaccine 
separated by at least 28 days, respectively. If the outbreak 
affects preschool-aged children or adults with community-wide 
transmission, a second dose should be considered for children 
aged 1 through 4 years or adults who have received 1 dose. 
In addition, during measles outbreaks involving infants aged 
<12 months with ongoing risk for exposure, infants aged ≥6 
months can be vaccinated. During mumps outbreaks involving 
adults, MMR vaccination should be considered for persons 
born before 1957 who do not have other evidence of immunity 
and might be exposed. Adequate vaccination during rubella 
outbreaks for persons aged ≥12 months consists of 1 dose of 
rubella-containing vaccine.
CDC guidance for surveillance and outbreak control for 
measles, rubella, CRS, and mumps can be found in the Manual 
for the Surveillance of Vaccine-Preventable Diseases (http://
www.cdc.gov/vaccines/pubs/surv-manual/index.html).
Outbreaks in Health-Care Facilities
During an outbreak of measles or mumps, health-care 
facilities should recommend 2 doses of MMR vaccine at the 
appropriate interval for unvaccinated health-care personnel 
regardless of birth year who lack laboratory evidence of measles 
or mumps immunity or laboratory confirmation of disease. 
Similarly, during outbreaks of rubella, health-care facilities 
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should recommend 1 dose of MMR vaccine for unvaccinated 
personnel regardless of birth year who lack laboratory evidence 
of rubella immunity or laboratory confirmation of infection 
or disease. Serologic screening before vaccination is not 
recommended during outbreaks because rapid vaccination is 
necessary to halt disease transmission (6). If documentation of 
adequate evidence of immunity has not already been collected, 
it might be difficult to quickly obtain documentation of 
immunity for health-care personnel during an outbreak or 
when an exposure occurs. Therefore, health-care facilities might 
want to ensure that the measles, rubella, and mumps immunity 
status of health-care personnel is routinely documented and 
can be easily accessed.
Postexposure Prophylaxis with 
MMR Vaccine
MMR vaccine, if administered within 72 hours of initial 
measles exposure, might provide some protection or modify the 
clinical course of measles (216–219,222). For vaccine eligible 
persons aged ≥12 months exposed to measles, administration 
of MMR vaccine is preferable to using IG, if administered 
within 72 hours of initial exposure. If exposure does not 
cause infection, postexposure vaccination should induce 
protection against subsequent exposures. If exposure results in 
infection, no evidence indicates that administration of MMR 
vaccine during the presymptomatic or prodromal stage of 
illness increases the risk for vaccine-associated adverse events. 
Postexposure MMR vaccination does not prevent or alter the 
clinical severity of rubella or mumps and is not recommended.
Postexposure Prophylaxis with Immune Globulin
If administered within 6 days of exposure, IG can prevent 
or modify measles in persons who are nonimmune. IG is not 
indicated for persons who have received 1 dose of measles-
containing vaccine at age ≥12 months, unless they are severely 
immunocompromised (as defined later in this report in the 
subsection titled Immunocompromised patients). IG should 
not be used to control measles outbreaks, but rather to 
reduce the risk for infection and complications in the person 
receiving it. IG has not been shown to prevent rubella or 
mumps infection after exposure and is not recommended for 
that purpose.
Any nonimmune person exposed to measles who received 
IG should subsequently receive MMR vaccine, which 
should be administered no earlier than 6 months after IGIM 
administration or 8 months after IGIV administration, 
provided the person is then aged ≥12 months and the vaccine 
is not otherwise contraindicated.
Recommended Dose of Immune Globulin for 
Postexposure Prophylaxis
The recommended dose of IG administered intramuscularly 
(IGIM) is 0.5 mL/kg of body weight (maximum dose = 15 mL) 
and the recommended dose of IG given intravenously (IGIV) 
is 400 mg/kg.
Recommendations for Use of Immune Globulin 
for Postexposure Prophylaxis
The following patient groups are at risk for severe disease 
and complications from measles and should receive IG: infants 
aged <12 months, pregnant women without evidence of 
measles immunity, and severely immunocompromised persons. 
IGIM can be administered to other persons who do not have 
evidence of measles immunity, but priority should be given 
to persons exposed in settings with intense, prolonged, close 
contact (e.g., household, daycare, and classroom). For exposed 
persons without evidence of measles immunity, a rapid IgG 
antibody test can be used to inform immune status, provided 
that administration of IG is not delayed.
Infants aged <12 months. Because infants are at higher 
risk for severe measles and complications, and infants are 
susceptible to measles if mothers are nonimmune or their 
maternal antibodies to measles have waned (337), IGIM 
should be administered to all infants aged <12 months who 
have been exposed to measles. For infants aged 6 through 11 
months, MMR vaccine can be administered in place of IG if 
administered within 72 hours of exposure.
Pregnant women without evidence of measles immunity. 
Because pregnant women might be at higher risk for severe 
measles and complications (20), IGIV should be administered 
to pregnant women without evidence of measles immunity 
who have been exposed to measles. IGIV is recommended to 
administer doses high enough to achieve estimated protective 
levels of measles antibody titers.
Immunocompromised patients. Severely immunocompro-
mised patients who are exposed to measles should receive IGIV 
prophylaxis regardless of immunologic or vaccination status 
because they might not be protected by the vaccine. Severely 
immunocompromised patients include patients with severe 
primary immunodeficiency; patients who have received a bone 
marrow transplant until at least 12 months after finishing all 
immunosuppressive treatment, or longer in patients who have 
developed graft-versus-host disease; patients on treatment for 
ALL within and until at least 6 months after completion of 
immunosuppressive chemotherapy; and patients with a diag-
nosis of AIDS or HIV-infected persons with severe immuno-
suppression defined as CD4 percent <15% (all ages) or CD4 
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count <200 lymphocytes/mm3 (aged >5 years) and those who 
have not received MMR vaccine since receiving effective ART. 
Some experts include HIV-infected persons who lack recent 
confirmation of immunologic status or measles immunity.
For persons already receiving IGIV therapy, administration 
of at least 400 mg/kg body weight within 3 weeks before 
measles exposure should be sufficient to prevent measles 
infection. For patients receiving subcutaneous immune 
globulin (IGSC) therapy, administration of at least 200 mg/kg 
body weight for 2 consecutive weeks before measles exposure 
should be sufficient.
Future Directions
To maintain measles, rubella, and CRS elimination, and 
control of mumps in the United States, rapid detection of cases 
is necessary so that appropriate control measures can be quickly 
implemented. This is to prevent imported strains of virus 
from establishing endemic chains of transmission.  Pockets 
of unvaccinated populations can pose a risk to maintaining 
elimination of measles, rubella, and CRS and control of 
mumps, because these diseases will continue to be imported 
into the United States as long as they remain endemic globally. 
The key challenges to maintaining measles, rubella, and 
CRS elimination and control of mumps in the United States 
are 1) ensuring high routine vaccination coverage which 
means vaccinating children at age 12 through 15 months 
with a first dose of MMR vaccine and ensuring that school-
aged children receive a second dose of MMR vaccine (for 
measles and mumps), 2) vaccinating high risk groups such 
as health-care personnel, international travelers, including 
infants aged 6 through 11 months, and students at post-high 
school educational institutions, 3) maintaining awareness of 
these diseases among health-care personnel and the public, 
4) working with U.S. government agencies and international 
agencies, including WHO, on global measles and rubella 
mortality reduction and elimination goals, and 5) ensuring that 
public health departments continue conducting surveillance 
and initiating prompt public health responses when a suspect 
case is reported.   
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